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Inflammation is a crucial defense mechanism that protects the body from the devastating 
effects of invading pathogens. However, an unrestrained inflammatory reaction may 
result in systemic manifestations with dire consequences to the host.  The extent of 
activation of the inflammatory response is tightly regulated through immunological and 
neural pathways. Previously, we demonstrated that cholinergic stimulation confers 
enhanced protection in experimental animals orally infected with a lethal dose of 
Salmonella typhymurium. In this study, we investigated the mechanism by which this 
enhanced protection takes place. We showed that cholinergic stimulation enhanced host 
survival following oral-route infection, which correlated with significantly reduced 
bacterial load in target organs, including livers and spleens. Enhanced protection was 
not due to increased gut motility or rapid bacterial clearance from the GI tract. 
Moreover, protection against bacterial infection was lost when the animals were infected 
systemically, suggesting that the acetylcholine-mediated protective effect was mostly 
confined to the gut mucosal tissue. In vivo imaging demonstrated more localized 
infection and delay in bacterial dissemination into systemic organs in mice pre-treated 
with acetylcholinesterase inhibitors. Morphological analysis of the small intestine 
(ileum) showed that acetylcholinesterase inhibition induced the degranulation of goblet 
cells and Paneth cells, two specialized secretory cells involved in innate immunity. Our 
findings demonstrate a crucial pathway between neural and immune systems that acts at 
the mucosal interface to protect the host against invading pathogens. 
 
Keywords: acetylcholinesterase inhibition, Salmonella, neuro-immune, intestine, 




Title and Abstract (in Arabic) 
 
مثبطات األستيل كولين استيراز االستجابة المناعية المضادة اآلليات التي تنظم بها 
 للجراثيم
 
عملية االتهاب تعتبر من أهم وسائل الدفاع عن الجسم و التي يتحتم تنظيمها و إال تسببت بضرر 
 كبير للجسم و يتم تنظيمها بالتنسيق بين جهازالمناعة و الجهاز العصبي.
العصبي االستيل كولين أدى إلى حماية الفئران من عدوى  دراسة سابقة بينت أن رفع مستوى الناقل
 في دراستنا الحالية نعمل على تحديد اآلليات المسؤولة عن هذه الوقاية.السالمونيال القاتلة، و عليه 
أوضحت النتائج أن هذه الوقاية مرتبطة بانخفاض التعداد الجرثومي في مختلف األعضاءوتعتمد 
رثومية حيث أن التأثير وجد فقط عند إعطاء العدوى فمويا. و قد تبين على كيفية حصول العدوى الج
أن هذه الوقاية ليست ناتجة عن زيادة حركة األمعاء و بالتالي التصريف السريع للجرثومة و إنما 
بسبب انحصارها في القناة الهضمية و بالتالي تأخر انتشارها إلى بقية أعضاء الجسم. مورفولوجيا 
استيراز  ولين عن طريق تثبيط األستيل كوليناألستيل ك مستويات دةة أوضحت أن زيااألمعاء الدقيق
أدى إلى تحفيز تفريغ محتويات خاليا إفرازية متخصصة في األمعاء مثل خاليا بانيت و الخاليا 
 الكأسية اللتان تعتبران جزء من المناعة األولية.
لعصبي و جهاز المناعة على صعيد األغشية ختاما، نستنتج من دراستنا وجود تفاعل بين الجهاز ا
المخاطية الموجودة في القناة الهضمية و التي ساهمت في حماية الجسم المضيف من عدوى 
 السالمونيال القاتلة.
مناعي، األمعاء، عائق -مثبطات األستيل كولين استيراز، سالمونيال، عصبيالكلمات المفتاحية: 
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Chapter 1 : Introduction  
1.1 Acetylcholine 
Acetylcholine (ACh) is an important neurotransmitter in the autonomic nervous system. 
It is the pre- and postganglionic neurotransmitter in the parasympathetic nervous system 
as well as the preganglionic neurotransmitter in the sympathetic nervous system. ACh is 
synthesized from acetyl CoA and choline in the presynaptic neurons by the enzyme 
choline acetyltransferase (ChAT), at that point the vesicular acetylcholine transporter 
(VAChT) is responsible for leading the ACh into the vesicles to be stored until it is 
needed. When a nerve is stimulated, ACh containing vesicles will be mobilized by the 
influx of calcium ions through the membrane, fuse with the presynaptic membrane and 
release ACh into the synaptic cleft, in the case of neurons, or into the neuromuscular 
junction in muscles. ACh will, then, bind to its receptors which are expressed on the 
post-synaptic membrane.  
Two types of ACh receptors are known: the muscarinic acetylcholine receptors 
(mAChR) and the nicotinic acetylcholine receptors (nAChR). mAChRs are G-protein 
coupled receptors which are classified into five subtypes M1, M2, M3, M4 and M5 
which vary in their distribution in the central and peripheral nervous systems, and 
different organs and cells (1). nAChRs are pentameric ligand-gated ion channels with 
different types of subunits depending on whether the receptors are located in neurons or 
in muscles. In neurons, the nAChR subunits can be either α (ranging from α2 to α10) or 
β (ranging from β2 to β4) and they can be arranged as homomeric receptors like α7 
nAChR or heteromeric receptors like (α4)2(β2)3. The nAChR in muscles is an 
heteromeric structure composed of 2 α1 subunits and one of each of β1, γ (or ε) and δ 
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(1,2). To finalize the ACh signaling, ACh is hydrolyzed by acetyl cholinesterase (AChE) 
to acetic acid and choline. Choline is then reabsorbed into the pre-synaptic neuron via a 
high-affinity choline transporter to be reused in synthesizing ACh (2). Diagram 1 shows 















Diagram 1: Acetylcholine life cycle 
Cholinergic nerve transmission is terminated by the enzyme 
acetylcholinesterase (AchE). AchE is found both on the post-synaptic 
membrane of cholinergic synapses and in other tissues e.g. red blood cells. 
Acetylcholine (Ach) binds to AchE and is hydrolysed to acetate and 






1.2 Non-neuronal cholinergic system 
 
The existence of a cholinergic system in many non-neuronal mammalian cells is well 
known. These cells contain the main components of the cholinergic system which are: 
 ACh 
 ChAT thus the ability to synthesize ACh  
 AChE hence the ability to hydrolyze ACh  
 n-AChRs and m-AChRs for ACh to interact  
Furthermore, the presence of ACh and ChAT has been demonstrated in evolutionary 
primitive life like fungi and bacteria (E.coli, Staphylococcus aureus and Bacillus 
subtilis) and multicellular organisms for example sponge as well as in plants such as 
bamboo shoot, eggplant and mushrooms (3).  
Examples of non-neuronal mammalian cells that express ChAT are: 
 Human placenta and airway epithelial cells which manifest ChAT activity in 
plasma membranes and associated structures such as microvilli, cilia, caveolae, 
cytosol and nucleus. The expression of ChAT in such important and functional 
areas is linked with the cellular functions (ciliary activity, proliferation, 
differentiation and organization of the cytoskeleton) of the non-neuronal ACh 
produced by these cells (4). 
 Murine embryonic stem cell line (CGR8) which is able to synthesize and release 
ACh involved in the regulation of phenotype-specific cell function and in 
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cellular homeostasis. Moreover, CGR8 cell line express functional nicotinic and 
muscarinic ACh receptors (5). 
 Mice cardiac myocytes which have the capability to synthesize ACh. In these 
cells ACh has been shown to reduce cellular oxygen consumption, accelerate 
angiogenesis and up-regulate cardiac ischemic tolerance factor HIF-1α (hypoxia-
inducible factor-1 alpha) which all lead to the prevention of cardiac myocyte 
ischemia thus has a protective role (6). Moreover, Oikawa et al. (7) demonstrated 
that the non-neuronal cholinergic system is able to regulate the levels of ATP 
and survival of cells under serum deprived conditions. ACh in ChAT-expressing 
cells can increase cellular ATP levels and increase glucose up-take by inducing 
the expression of HIF-1α, a transcription factor responsible for glucose 
utilization, glucose up-take and glycolysis, thus maintaining cell energy and 
protecting it from death (7). 
1.3 Cholinergic system in the immune cells 
 
In the immune system, immune-competent cells contain all the components of the 
cholinergic system as they have the ability to synthesize, release and metabolize 
acetylcholine on their own, independently of the nervous system, although the 
expression of these components vary from cell to cell. It has been demonstrated that 
60% of ACh present in blood is indeed localized in circulating mononuclear leukocytes 
(MNL) (8). Additional studies on cell lines have revealed that human T-lymphocytes 
express ChAT which is identical to the ChAT expressed in the nervous system 
indicating that the origin of ACh in the blood is from the MNLs (9).  
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The expression of muscarinic ACh receptors in the MNL was evaluated repeatedly, yet 
conflicting data were obtained. Two studies (10,11) found that MNL express M3, M4 
and M5 subtypes while M1 and M2 mRNA were not detected. However, another study 
performed on MNL from different donors showed that M4 and M5 were expressed in all 
the individuals but the expression of M1, M2 and M3 varied among them (12). It was 
also demonstrated the presence of neuronal nicotinic ACh receptors in MNL with α2, α5 
and α7 subunits but not α3, α4, β3 and β4 subunits. In some subjects α6 and β2 were 
expressed indicating the diversity of muscarinic receptor subtypes and nicotinic 
receptors subunits expressed by MNL among the different individuals (12).  
The presence of different cholinergic components has been described in murine MNLs, 
dendritic cells (DCs) and macrophages. ChAT was not expressed in resting MNLs, DCs 
and macrophages; however, upon stimulation ChAT expression was induced in MNLs 
and DCs but not macrophages. Furthermore, all subtypes of muscarinic receptors (M1-
M5) were expressed on the three cell types. In addition, α2, α5, α6, α7, α10 and β2 
nicotinic receptors subunits were expressed in the three cell types while α4, α9 and β4 
expression varied. Interestingly, α3 and β3 encoding mRNA was not detected in any of 
the cell types. Moreover, AChE was expressed by the three cell types indicating that 
ACh is either synthesized by these cells or act on these cells through AChRs (13). 
1.4 Cholinergic modulation of the immune cells 
 
Several studies have shown contradictory effects of cholinergic stimulation on different 
immune cells. In human leukemic cell lines it has been demonstrated that ACh, released 
from T cells acted (through M1 ACh receptor) in an autocrine/paracrine manner on T 
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and B lymphocytes elevating intracellular free calcium levels and subsequently 
increasing c-Fos mRNA expression (14). Furthermore, when human peripheral blood 
mononuclear cells, monocytes and whole blood were treated with nicotinic agonists and 
then stimulated with a TLR agonist, pro-inflammatory responses were inhibited but not 
the production of the anti-inflammatory cytokine IL-10. Surface expression of TLR2 
and TLR4 were also down-regulated and these responses were found to be mediated by 
activation of the Jak2/STAT3 pathway (15).    
Studies on IL-4 stimulated pulmonary endothelial cell line revealed that ACh, nicotine 
and muscarine inhibited the expression of the adhesion molecule E-selectin and vascular 
endothelial growth factors (16). Similarly, in a mouse in-vivo model, cholinergic agonist 
and vagus nerve stimulation were found to block leukocytes/endothelial adhesion and 
leukocytes migration. These effects were found to be partially mediated through n-
AChRs (17). 
Activation of muscarinic receptors has been shown to have a pro-inflammatory effect on 
mice as they induced an antibody response and T cell proliferation, they did not prevent 
leukocytes infiltration and resulted in tissue injury. Moreover, these effects were 
inhibited by muscarinic antagonists (18). Nicotinic receptors in particular, α7, inhibited 
the release of TNF-α from macrophages and neutrophil recruitment resulting in an anti-
inflammatory effect in mice (19).  
Furthermore, the effect of cholinergic stimulation varies in different immune cell types. 
Nicotine administration reduced the surface expression of CD11b in neutrophils by 
suppressing F-actin polymerization, the surface expression of β2-integrin and leukocyte 
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chemotaxis (20). Cholinergic activation in dendritic cells induced an increase in the 
expression of CD86 and the release of TNF-α and IL-8. When cholinergic activated 
dendritic cells were stimulated with LPS, a reduction of T cell priming ability, TNF-α 
and IL-12 production were observed (21). Additionally, nicotinic receptor activation on 
stimulated CD4+CD62L+ T cells resulted in up-regulation of IFN-γ and down-
regulation of IL-17 production. However, muscarinic receptor activation  on these cells 
up-regulated IL-10 and IL-17 production and down-regulated IFN-γ (22). CD8 T cells 
were also showed to be regulated by ACh as M1 mAChR was found to be engaged in 
the differentiation of CD8 cells to cytotoxic lymphocytes (23). Moreover, α7 nAChR in 
B cells was found to be coupled to CD40 and to have an inhibitory effect, on the 
contrary α4β2 nAChR coupled to IgM, has a stimulatory effect (24).  
α7 nAChR are involved in the regulation of IgG1 and inflammatory cytokines like IL-6, 
TNF-α and IFN-γ production most likely in an inhibitory manner (25). In contrast, 
activation of M1 and/or M5 mAChRs elevate the production of inflammatory cytokines 
like IL-6 and IgG1 production by mediating antibody class switching from IgM to IgG1 
(26). 
It has been shown that some parasitic infection can regulate the inflammatory responses 
through non-neuronal cholinergic system. Ttypanosoma evansi parasite infection 
induced an increase in the production of AChE in rat lymphocytes during the acute 
phase of infection that is characterized by high number of circulating parasites. High 
levels of AChE reduce the levels of ACh and promote inflammatory responses. In the 
chronic phase of the disease where the number of circulating parasites decreased AChE 
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levels were reduced and therefore promoted ACh mediated anti-inflammatory responses 
(27).      
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1.5 The inflammatory reflex 
 
The presence of muscarinic and nicotinic receptors on immune cells and the fact that 
vagus nerve (a major parasympathetic nerve) innervates lymphoid tissues suggested that 
ACh may act as a neuro-immunomodulator in the interactions between the nervous and 
immune systems. Tracy and group demonstrated for the first time that the interaction 
between the immune and nervous systems is vital for modulating immune responses and 
controlling inflammation (28). Initially it was thought that the cholinergic stimulation of 
the splenic macrophages, mediated by the α7 AChR, was directly via the vagus nerve 
and it was named “cholinergic anti-inflammatory pathway” (28,29). Later investigations 
demonstrated that the vagus nerve does not directly innervate the spleen instead it 
innervates the celiac ganglion and stimulates the adrenergic splenic nerve which relays 
the stimulation to the splenic macrophages through splenic T cells (30).     
So the link between the nervous system being the master of the body and the immune 
system has been well established and therefore the immune responses are regulated by 
the two arms of the autonomic nervous system through what is called the “inflammatory 
reflex”. In the inflammatory reflex, the presence of endogenous or exogenous molecular 
products of inflammation in the periphery can stimulate the afferent action potential and 
relay the signal to the central nervous system particularly the brain (31). Then, an 
efferent action potential will be sent through the vagus nerve and results in the release of 
ACh in the celiac ganglion. There ACh will bind to the α7 nAChR on the adrenergic 
splenic nerve (30,32). Subsequently, splenic nerve will convey the signal by the release 
of the neurotransmitter noradrenaline in the spleen which will bind to β2-adrenergic 






 T cells. A specific subset of 
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) has been found to be responsible for the 
production of ACh upon adrenergic stimulation (34,35). Then, ACh will bind to α7 
nAChR expressed on the macrophages (29) resulting in the inhibition of the production 
of anti-inflammatory cytokines like IL-1 and TNF-α thus reducing the inflammatory 








Diagram 2: The inflammatory reflex 
The prototypical reflex circuit regulating immunity is comprised of afferent and 
efferent signals transmitted in the vagus nerve in response to the molecular 
products of infection and injury, including cytokines, eicosanoids, DAMPs, and 
PAMPs. The activation of adrenergic neurons in the spleen culminates in the 
release of norepinephrine in the vicinity of T cells that are capable of secreting 
acetylcholine. Acetylcholine crosses the marginal zone and enters the red pulp, 
where it interacts with α7 nAChR expressed on cytokine producing macrophages. 
α7 nAChR signal transduction suppresses the synthesis and release of TNF, IL-1, 
IL-18, HMGB1, and other cytokines.  
Obtained from: Ulf Andersson and Kevin J. Tracey, Neural reflexes in 





Activation of the inflammatory reflex by vagus nerve stimulation, selective α7 nAChR 
agonist and other ACh mimicking agents has been studied in murine endotoxemia and 
sepsis models. Cholinergic stimulation improved the survival of mice through reducing 
TNF-α circulating levels thus protecting the vital organs from TNF-induced tissue injury 
during sepsis and preventing multiple organs failure (28,36).  
The splanchnic artery occlusion (SAO) shock model is characterized by systemic 
inflammatory responses due to an increase in the production of TNF-α, an accumulation 
of neutrophils in the different tissues, especially in lungs and liver, and eventually organ 
failure. Vagus nerve stimulation in a SAO animal model resulted in a reduction in the 
NF-κB activation and reduces mRNA expression of TNF-α with subsequent reduction of 
TNF-α level in the circulation. Moreover, vagus nerve stimulation caused a reduction in 
leukocytes accumulation in the ileum and lungs which could be a result of the 
amelioration of inflammatory cascade through reducing circulation TNF-α. These 
modulations through vagus nerve stimulation improved the mice survival time and rate 
which lead to a protective effect (37).   
In animal models of inflammatory diseases like acute kidney injury, obesity and 
collagen-induced arthritis has been shown that cholinergic stimulation lead to a 
reduction in the inflammatory responses and had a protective role (38–40).    
The effect of the cholinergic stimulation in a live infectious model seems to be 
controversial. In a peritonitis model with live bacteria (E.coli) cholinergic stimulation 
reduced the pro-inflammatory cytokines and cell recruitment in mice, however it worsen 
the clearance of bacteria and survival rate of the animals in comparison to control mice 
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(36). These effect was reversed in α7 nAChR deficient mice which have faster 
neutrophils recruitment (41). Similarly, when the anti-inflammatory reflex pathway was 
inhibited by eliminating the noradrenergic neurons in an murine model of peritonitis 
induced by Klebsiella pneumonia, the animal survival was improved (42). On the 
contrary, previous administration of AChE inhibitor improved the survival of mice after 
a lethal infection with S. typhimurium (43); moreover, M3 m-AChR activation improved 
Th1 adaptive immune responses in Salmonella infection by inducing IFN-γ production 
and Th2 adaptive immune responses in Nippostrongylus brasiliensis infection by 
inducing IL-13 production, resulting in a protective effect (44).  
1.6 Immuno-physiology of the gastrointestinal tract  
 
The main role of the gastrointestinal tract (GIT) is digesting and absorbing different 
nutrients that are needed for survival. GIT also confers the first line of defense against 
orally ingested microorganisms and food antigens. The defensive factors vary from 
saliva, gastric acidity, mucus intestinal flora, peristaltic movement epithelial cell 
membrane to intracellular junctional complexes that prevent the foreign matters from 
crossing the epithelium and eliminate them (45).  
The intestine has different innate immune mechanisms (mechanical, chemical and 
cellular) to protect the gut mucosa from microbial infections: the first is a mechanical 
mechanism that includes the epithelium, peristalsis and mucus coating; the second is a 
chemical mechanism given by specific anti-microbial peptides, proteins, PAMs 
(pathogen recognition molecules) and cytokines secreted by the intestinal cells; and 
finally, there is a third mechanism, the cellular mechanism, which includes the epithelial 
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cells, macrophages, dendritic cells, NK cells and γδ T cells. These three components act 
at different levels: extra-epithelial, epithelial and subepithelial levels (46).  The 
components that act at the extra-epithelial level include anti-microbial proteins and 
peptides secreted by a group of cells located at the base of the crypts of Lieberkuhn, in 
the distal part of the small intestine, called Paneth cells. The Paneth cells are rich in 
secretory granules containing microbicidal peptides and proteins, like lysozyme, 
phospholipase A, cryptdins, cryptdin-related sequence peptides (CRS), RegIIIγ and 
angiogenin 4, that contribute to the intestinal innate immunity (47,48). It has been 
demonstrated that the interaction between the pathological microorganisms and the 
Paneth cells results in an increased concentration of the anti-microbial peptides in the 
intestinal lumen (49). Secretory phospholipase A2 is released upon stimulation by 
bacterial products and it has been shown to have bactericidal activity against Salmonella 
typhimurium and Listeria monocytogens (50,51). It has been also demonstrated that 
angiogenins are present in the secretory granules of the Paneth cells and are released 
upon stimulation by bacterial products (52). 
Among all the antibacterial products secreted by the Paneth cells, cryptdins (alpha-
defensins in humans) are the most abundant accounting for 70% of the released peptides 
with anti-bacterial activity (49). Cryptdins are small cationic cysteine-rich anti-microbial 
peptides belonging to the alpha-defensin family and specific to Paneth cells. They are 
synthesized as pre-peptides and, then, processed to active peptides by matrix 
metalloproteinase matrilysin (MMP-7). Their bactericidal activity of the cryptdins is due 
to their chemical structure characterized by tridisulfide array and amphipathicity (53–
55) which induce the formation of membrane spanning pores in the bacterium leading to 
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its lysis (46,47). Several studies have shown the essential role that cryptdins play in the 
mucosal immune defense to Salmonella infection. Transgenic mice that overexpressed 
cryptdins in the Paneth cells are more resistant Salmonella enterica serovar typhimurium 
infection (56) whereas mice with deficiency in cryptdins processing are more sensitive 
to oral infection by Salmonella (57).  
Moreover, goblet cells located in the crypt are known to synthesize and release mucin to 
form the thick mucus layer in response to mechanical insult, chemical irritation and 
bacterial toxins. Goblet cells morphologically composed of theca containing mucus 
granules that lay beneath the apical membrane (58). Mucus layer that covers the 
intestinal lumen is made of a mesh-like viscous, permeable and gel forming glycoprotein 
(mucin) (59). This mucus layer not only contains mucin but also anti-microbial peptides 
secreted by Paneth cells and secretory IgA (60). Mucus layer acts as a barrier to protect 
the host from invading oral pathogens and also it act as a lubricant (59,60).    
Gut-associated lymphoid tissue (GALT) (Diagram 3) is composed of different 
immunological structures which are important in the host intestinal defense. Those 
structures are organized lymphoid tissues such as mesenteric lymph nodes and Peyer’s 
patches and diffusely scattered lymphocytes in the intestinal lamina propria and 
intraepithelium (61).  
Peyer’s patches (PPs) are organized lymphoid tissues that vary in number: 8-10 in mice 
and hundreds in humans (62). In general, PPs are composed of three regions: the 
follicle-associated epithelium (FAE), subepithelial dome (SED) and follicular region.  
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PPs have efferent but not afferent lymphatic vessels thus to compensate, the FAE of PPs 
which is a specialized epithelial region contains specialized antigen-sampling microfold 
cells (M cells). M cells are enterocytes that exhibit at their apical surface a poorly 
organized brush border with short microvilli and thin mucus layer. Their cytoplasm 
contains small endocytic vesicles with transcytosis capability which allows these cells to 
sample the contents in the lumen (particulate matters and pathogens) and transport them 
across the epithelium to the basolateral memebrane (49,50,51).  
SED region has abundancy of dendritic cells (DCs) which can engulf the antigens 
transported by the M cells, process them and present them to the mucosal T and B cells 
in order to generate antigen-specific response. DCs constitute around 10% of the total 
population of the PPs. B cells located at the follicular region are the most abundant cells 
in the PPs, constituting around 60% of the total population. Additionally, T cells 
comprise around 25% of the PPs in which 45% of the T cells are CD4+, 35% are CD8+ 
and 20% are CD4-/CD8- T cells. T cells are mostly located at the interfollicular region 
(IFR) (66).     
Mesenteric lymph nodes (MLN) are present at the intestinal mesentery. Morphologically 
MLN have three compartments: the cortex which has follicles that composed B cells and 
dendritic cells, paracortex that contains high percentage of T cells and dendritic cells 
and lastly the medulla that contains B cells and T cells (67). Dendritic cells carrying the 
antigen, migrate from the intestinal epithelium to the MLNs where they present the 
antigen particles to the naïve T cells in the paracortex which results in activation of the 
adaptive immune responses. Afterwards, the effector T cells will leave the MLNs and 
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migrate to other organs (67,68). B cells in MLN contribute to the release of secretory 
IgA in the gut lumen (69).  
Finally, the intestinal lamina propria (LP), located between the epithelium and 
muscularis mucosa, and it contains a variety of lymphoid cells like IgA producing 
plasma cells, T cells, dendritic cells, macrophages and mast cells. In the intraepithelial 
space between the tight junctions and the basal membrane of the gut epithelium, 
intraepithelial lymphocytes are located. These lymphocytes are T cells both, CD8+ and 
CD4+ cells that do not need antigen presentation; instead they can release cytokines 











Diagram 3: Schematic representation of the lymphoid elements of the intestinal 
immune system 
The organized tissues of the Peyer's patches and mesenteric lymph nodes (MLNs) 
are involved in the induction of immunity and tolerance, whereas the effector sites 
are scattered throughout the lamina propria and epithelium of the mucosa. Both 
the Peyer's patches and villus lamina propria are drained by afferent lymphatics 
that go to the MLNs. SED, subepithelial dome; TDA, thymus-dependent area. 
Obtained from: Mowat AM. Anatomical basis of tolerance and immunity to 




1.7 Effect of the cholinergic system on the intestinal cells 
 
Sympathetic and parasympathetic autonomic nervous systems are well known to 
innervate the gastrointestinal tract (GIT) and regulate GI motility, secretions and 
material absorption. Furthermore, the existence of non-neuronal cholinergic system has 
been established in the GI epithelial cells and the intestinal resident immune cells. 
Anatomical studies revealed that cholinergic enteric neurons innervate and are located in 
close proximity to macrophages, plasma cells and lymphocytes present in the lamina 
propria in addition to the lymphocytes in the Peyer’s patches. Epithelial cells in the 
gallbladder and lower intestine along with M cells and T cells in the Peyer’s patches 
were shown to express non-neuronal ChAT thus they were able to synthesize ACh (71). 
Furthermore, cholinergic as well as adrenergic neurons were found to be present in a 
close proximity to secretory epithelial cells in the intestinal crypt and IgA producing 
cells in the intestine (72). The postoperative ileus is an animal model characterized by a 
localized bowl inflammation that results in dysfunctional bowel movement, 
accumulation of gas, abdominal distention and other gastric symptoms. In this model it 
was shown that intestinal inflammation activated the afferent vagus nerve which in term 
activated the efferent arm of vagus nerve, mainly the neurons innervating the inflamed 
area in the intestine (73) which indicates that the cholinergic nervous system could 
modulate the immune responses in the intestinal area.  
The inflammatory response was found to be initially induced by the resident intestinal 
muscularis macrophages (74). Moreover, it was also shown that specific α7 nAChR 
agonist as well as vagus nerve stimulation had an anti-inflammatory effect that was 
mediated through the reduction in the transcriptional activity of NF-κB and the 
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induction of STAT3 phosphorylation (activate Jak2/STAT3 pathway) in the 
macrophages thus inhibiting the inflammatory responses (75). This anti-inflammatory 
effect of the vagus nerve stimulation was mediated by the direct interaction of the vagus 
nerve with the gut resident intestinal muscularis macrophages and independent of the 
spleen (76). Additionally, vagus nerve stimulation was shown to enhanced luminal 
uptake as well as the phagocytic ability of the lamina propria resident macrophages 
despite of inhibiting the activation of NF-κB and reducing the production of pro-
inflammatory cytokines. These effects were due to the binding of ACh to the α4β2 
nAChRs on macrophages (77).  
Several evidence showed that intestinal epithelium synthesizes ACh that regulates 
growth and differentiation of epithelial stem cells via muscarinic ACh receptors (78). 
Moreover, it was demonstrated that ACh stimulation induced degranulation of mucin 
granules causing a massive release of mucin to the intestinal lumen (79).  
Additionally, Paneth cells were also able to respond to ACh through their muscarinic 
AChRs. ACh stimulation induced massive exocytosis of the AMPs containing granules 
into the lumen (80,81). A study on the ultra-structural analysis of the Paneth cells from 
rats subjected to bilateral subdiaphragmal trunkal vagotomy, revealed a profound 
ultrastructural re-arrangement in the cytoplasm and an increase in the total amount of 
secretory granules (82). Moreover, the secretion of Paneth cells was blocked when mice 
were subjected to atropine treatment (81). 
In humans, it has been shown the importance of Paneth cells and the secretion of 
defensins on maintaining healthy intestinal mucosa. A reduction in the antibacterial 
19 
 
activity in the intestinal mucosal extracts and a decrease in the expression of alpha-
defensins by Paneth cells has been reported in patients with Crohn’s disease (83) 
resulting in luminal bacterial overgrowth and increase in the number of Paneth cells, not 
only in the small intestine but also in the large intestine (metaplasia). These observations 
confer to Paneth cells a role in the pathogenesis of intestinal inflammation. 
In response to the presence of an antigen in the gastric mucosa, plasma B cells present in 
the intestinal epithelium (Peyer’s patches, isolated lymphoid follicules and lamina 
propria) and MLN were able to produce secretory IgA that act as one of the defensive 
mechanisms in the gut (69,84,85). As mentioned earlier, cholinergic and adrenergic 
neurons are present in close proximity to IgA producing plasma cells which could 
indicate the ability of these neurons to regulate the secretory IgA production. It has been 
demonstrated that ACh and adrenaline, through muscarinic ACh receptors and 
adrenergic β2 receptors, respectively, expressed on the surface of the epithelial cells in 
the crypt and intestine, stimulated the release of secretory IgA to the lumen suggesting a 
protective role of these neurotransmitters in the intestine (72). 
1.8 Acetyl cholinesterase inhibitors 
 
Acetyl cholinesterase is an enzyme present in the synaptic cleft that hydrolyzes the ACh 
in order to terminate its action (86). The administration of AChE inhibitors increases the 
concentration of ACh in the synaptic cleft and therefore, induces the hyper-stimulation 
of target cell. Acetyl cholinesterase inhibitors are administered to patients with 
myasthenia gravis and Alzheimer’s disease to reduce the deteriorating symptoms (87). 
In animal models the effect of AChE inhibitors on the immune system is not clear and it 
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seems to be contradictory. Most probably, this variability is due to the use of different 
experimental models, different AChE inhibitors with different dosages and exposure 
time. In a murine model of experimental autoimmune encephalomyelitis (EAE), 
rivastigmine an AChE inhibitor was found to reduce neurons axons demyelination and 
inflammatory infiltration of T cells and microglial cells which subsequently ameliorated 
the clinical symptoms and improved the spatial memory in mice. Moreover, 
rivastigmine has been shown to reduce the production of pro-inflammatory cytokines 
IL-17, IFN-γ and TNF-α which was mediated by the activation of α7 nAChRs (88). 
Likewise, galantamine, another AChE inhibitor, and through α7 nAChRs reduced TNF-
α production and improved mice survival in a murine endotoxemia model (89). In 
addition, AChE inhibitors like tacrine, rivastigmine and neostigmine reduced the LPS 
induced production of IL-1β in the brain and blood (90). On the other hand, in a murine 
model it was demonstrated that the administration of AChE inhibitor pyridostigmine 
bromide did not inhibit the production of IL-2 or IFN-γ by T cells (91). Likewise, in 
mice, the sub-chronic administration of organophosphorus compound dimethoate 
(another AChE inhibitor) resulted in a pro-inflammatory effect in the brain and it 








1.9 Experimental model 
1.9.1 Paraoxon as an AChE inhibitor 
In our experimental model we use paraoxon as AChE inhibitors. Paraoxon (O, O-diethyl 
O-p-nitrophenyl phosphate) is the bioactive metabolite of the organophosphate pesticide 
parathion (O, O-diethyl O-p-nitrophenyl phosphorothioate). De-sulphuration of 
parathion by liver enzymes, or sunlight, results in the formation of paraoxon, which 
inhibits AChE activity. Paraoxon mechanism of action is through a non-reversible 
binding to the active site of the AChE which makes the enzyme unable to hydrolyze the 
endogenous substrate (ACh) and therefore inhibits its activity. The effect of paraoxon on 
the immune system is not well defined and still controversial. In-vitro studies showed 
that paraoxon induced apoptosis in EL4 cell line (93,94). In rats, administration of 
paraoxon was found to induce the production of free radicals in different organs such as 
brain, liver and spleen (95). In other studies paraoxon has shown to be immune-
suppressant and acts as a protective agent that regulates immune responses (96,97). Our 
group demonstrated in a murine model, that chronic exposure to paraoxon did not affect 
the normal immune responses and had no influence over the survival of mice following 
a lethal bacterial infection model (98). Later studies showed that sub-chronic exposure 







1.9.2 Salmonella infection model 
Salmonella enterica is a facultative intracellular gram negative bacterium that causes an 
enteric disease in humans as well as in mice. It is transmitted through oral-fecal route 
via contaminated food and water. Different serovars cause different diseases, such as 
human restricted S. enterica serovar Typhi causes Typhoid fever however; S. enterica 
serovar Typhimurium (S. typhimurium) causes a self-limited gastroenteritis in human 
while in mice it causes a systemic disease resembles the manifestations of Typhoid fever 
in human (99). After oral ingestion, Salmonella adheres to the epithelial cells in the 
intestinal wall and uses different mechanisms to invade (99). The major invasion 
mechanism of Salmonella is through the intestinal microfold cell (M cells).  Salmonella 
induces the ruffling of the M cells membrane which helps the bacteria to get internalized 
causing the death of the M cells. Afterwards, bacteria will travel either laterally along 
the basal lamina or deeper into the dome of the follicle (100). Salmonella can be also 
internalized through non-phagocytic enterocytes using virulence-associated type 3 
secretion system encoded by Salmonella Pathogenicity Island 1 (SPI-1) (99). Specific 
subtype of DCs/macrophages that express the chemokine CX3CR1 are involved in the 
uptake of Salmonella from the lumen to the lamina propria. Some studies suggested that 
CX3CR1 expressing phagocytes were responsible for the luminal sampling and 
destruction of the invading bacteria rather than transportation as the CX3CR1-difficient 
mice had higher bacterial load in the organs and higher susceptibility compared to the 
wild type (101,102). The invasion mechanisms of Salmonella are shown in diagram 4.     
Initially during Salmonella infection, innate immune mechanisms in the intestine such as 
the presence of mucus released from goblet cells in the crypt, along with the release of 
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anti-microbial peptides (AMPs) from Paneth cells residing at the bottom of the crypt, 
will be the first barrier encountered by Salmonella. Mucus layer composed of mucins (a 
family of glycoproteins) covers the surface of the epithelium resulting in a barrier that 
needs to be penetrated before bacteria gain access to the epithelial cells and penetrate 
them (99). The bactericidal action of the anti-microbial peptides resides in their capacity 
to disrupt the integrity of the bacterial cell membrane. The expression of some of these 
peptides like RegIIIβ/γ was increased in streptomycin pre-treated mice infected with 
Salmonella (103). Moreover, IL-23 produced by the epithelial cells was able to induce 
the production of IL-22 that subsequently lead to the induction of angiogenin 4 (Ang4) 
(104). Despite the fact that AMPs are lethal to Salmonella, this bacterium was found to 
reduce the expression of cryptdins (defencin in humans) and lysozyme in Paneth cells 
along with their granules content, however an increase in the number of Paneth cells, 
mitotic events in the crypt and apoptotic events in the villi was observed simultaneously 
(46,105).        
Salmonella that passed the first line of defense at the intestinal epithelium will encounter 
macrophages and dendritic cells which are the first responders in the intraepithelial 
tissue and part of the innate immune system. Cell wall components of the Salmonella 
which are called PAMPs (pathogen associated molecular patterns) will be recognized by 
the surrounding cells through PRRs (pathogen recognition receptors) present on their 
surface examples of PAMPs and TLRs recognize it are: lipopolysaccharide (LPS) by 
TLR4, bacterial lipoproteins by TLR1/2/6, flagellin by TLR5 and DNA by TLR9 (99). 
Once the cells recognize the pathogen they will produce inflammatory cytokines (IL-1, 
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TNF-α, IL-12, IL-18 and IL-6) and chemokines to recruit immune cells to the site of 
injury.  
During Salmonella infection, macrophages will produce IL-12 which is one of the major 
inducers of IFN-γ production by T cells and natural killer (NK) cells, as well as an 
essential cytokine for the differentiation of T helper cells to Th1 cells.  Additionally, 
macrophages are also able to produce IL-18 which was showed to be involved in the 
induction of IFN-γ production (as IL-12) but it is unable to induce T cells to develop to 
Th1. IL-18 and IL-12 have been reported to have synergistic effect, although IL-12 was 
more effective during Salmonella infection. The IL-12, IL-18 and IFN-γ axis was found 
to be crucial to limit bacterial burden in the systemic organs and improve overall host 
survival (106–108).  Together, TNF-α produced by macrophages and IFN-γ produced by 
T cells and NK cells are essential in the host defense against Salmonella due to their 
ability to activate the bactericidal activity in macrophages which leads to the reduction 
of live bacterial load in the different organs (110).  
A critical factor that is involved in the ability of macrophages to control the replication 
of intracellular pathogen is the presence of functional Nramp1 (natural resistance-
associated macrophage protein) molecule which is a transmembrane protein expressed 
on macrophages that acts as iron transporter (111). The absence of functional Nramp1 in 
mice lead to a reduction in the bactericidal activity of macrophages and subsequently an 
increased susceptibility to invading Salmonella such as BALB/c strain (112) that we use 
in our study.  
25 
 
IL-10 is an anti-inflammatory cytokine that plays a central role in the Salmonella as it 
limits the immune response to pathogen by inhibiting the production of radical oxygen 
and nitrogen species as well as TNF-α and IL-12 cytokines. The levels of expression of 
IL-10 mRNA during Salmonella infection varies depending on the genotype of the host, 
but in both resistant and susceptible mice the levels of IL-10 correlates with the bacterial 
load in the organs, the more bacterial burden the higher the levels of IL-10. However IL-
10 does not play a key role in the susceptibility to Salmonella infection (113).  
Cytotoxic CD8 T cells that are MHC Ia restricted were found to have a protective role 
during Salmonella infection as they limited the bacterial growth by producing perforin a 
pore forming molecule and granzyme A and B which has a proteolytic action and kill 
















Diagram 4: Schematic representation showing the different routes Salmonella can 
take in order to invade the intestinal mucosa 
(1) The major pathway of invasion is through M cell mediated transcytosis at the 
Peyer’s patches. (2) An alternative route is via uptake by enterocytes. (3) This route 
requires the injection of bacterial effector proteins by the SPI-1 Type 3 Secretion 
System that induce ruffling and uptake of the bacterium. Uptake through 
intercalating CX3CR1+ macrophages/DCs might represent an additional route of 
invasion. 
 
Obtained from: Broz P, Ohlson MB, Monack DM. Innate immune response to 
Salmonella typhimurium, a model enteric pathogen. Gut Microbes. 2012 






Chapter 2 : Hypothesis    
Following infection with virulent Salmonella, inflammatory cytokines are secreted as a 
response to the infection. An excess in the production of inflammatory cytokines 
(cytokine storm) leads to septic shock and death of the host. 
We hypothesize that by increasing the ACh levels, the inflammatory reflex is stimulated 
to control the cytokine storm produced after lethal infection, and, therefore, protect the 
host from septic shock. Other unknown mechanisms mediated by ACh could also be 
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Schematic diagram shows the hypothesized mechanism of 
protection by AChE inhibitoon which could be through the 
activation of the inflammatory reflex or through other 
unknown mechanism by limiting the infection progression.  
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Chapter 3 : Aim and Objectives of the Study 
We have previously demonstrated that inhibition of AChE enzyme by paraoxon 
increases host resistance to an oral infection with the Gram-negative bacterial pathogen 
Salmonella enterica serovar Typhimurium.  The overall aim of the current study was to 
investigate the cellular and molecular mechanism(s) by which the cholinergic nervous 
system influences the immune response to infection 
The specific objectives were to: 
 Utilize multi-colour flow cytometry to evaluate the effect of AChE inhibition on 
the cellular phenotype and activation status of lymphoid and myeloid cell 
populations at mucosal immune system sites, represented by mesenteric lymph 
nodes, as well as systemic sites, including spleen and peritoneal exudate cells. 
 Use quantitative PCR (qPCR) to investigate alterations in gene expression 
profiles in splenic immune cells following inhibition of AChE. 
 Characterize the immune response in paraoxon-pretreated mice, or their control 
counterparts, following oral or systemic infection with either attenuated or 
virulent strains of Salmonella typhimurium.  
 Investigate the kinetics of bacterial dissemination following oral infection using 
in vivo bioluminescent imaging technology.   
 Investigate the mucosal innate immune responsiveness of paraoxon-pretreated or 
control mice, focusing on the extent of production of several types of anti-
microbial peptides and other effector molecules.   
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 Investigate possible alterations in intestinal mucosal epithelial tissue and 
associated cell types (Paneth cells and goblet cells) as a consequence of 


















Chapter 4 : Materials and Methods 
4.1 Materials  
4.1.1 Experimental animals 
BALB/c mice were purchased from Harlan Olac (Bicester, UK) and bred in the animal 
facility at the College of Medicine and Health Science, United Arab Emirates University 
(UAEU). Male mice aged 8-12 weeks and weighed 22-26 grams were used for this 
study.  Animals were housed in plastic cages with a controlled light and dark cycle of 12 
h each at 24-26°C and received rodent chow and water ad libitum. All studies involving 
animals were carried out in accordance with, and after approval of the animal research 
ethics committee of the College of Medicine and Health Science, UAEU (Protocol 
no.AE/06/81).  
4.1.2 Solutions 
0.1 M phosphate buffer  
solution 1: 17.8g of Na2HPO4.2H2O in 1L distilled water  
solution 2: 2.27g of KH2PO4 in 200 ml distilled water 
 To adjust the pH, solution 2 was added, gradually, to solution 1 until pH became 7.4, 
then, it was filtered and stored at 4
ο
C. 
10 mM DTNB  
396.3 mg DTNB in 100ml phosphate buffer. Stored at -20
 ο
C 
6 mM ethoprorazine  








 200mg potassium ferricyanide, 50 mg potassium cyanide, 1g sodium bicarbonate and 
500 µl 100% Triton X-100 in 1L distilled water 
RBCs lysis buffer  
8.3g ammonium chloride, 1g potassium bicarbonate and 1.8ml of 5%EDTA in 1L of 
distilled water and filtered through 0.2µm filter 
Supplemented RPMI-1640 
 5% heat inactivated fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 
mM HEPES, 0.075% sodium bicarbonate, 1x essential amino acids, 0.5x non-essential 
amino acids, 50 µg/ml gentamicin, 100 U/ml penicillin, 100 µg/ml streptomycin, and 
5x10-5M 2-mercaptoethanol (2-ME). 
Griess reagent  
2.35 ml of phosphoric acid (86%), 1 g Sulfanilamide and 0.1 g Naphthylethylene 
diamine hydrochloride in 100 ml of distilled water. 
10x PBS 











0.1M sodium carbonate coating buffer  
7.13g of sodium bicarbonate and 1.59g of sodium carbonate in 1L distilled water, pH9.5 
0.2M sodium phosphate coating buffer  
12.49g of disodium hydrogen phosphate and 15.47 sodium dihydrogen phosphate in 1L 
of distilled water, pH6.5. 
Washing buffer 
 1xPBS (80g sodium chloride, 11.6g Disodium hydrogen phosphate, 2g potassium 
chloride and 2g potassium dihydrogen phosphate in 10L distilled water) and 0.05% 
Tween-20, pH7). 
Assay diluent  
10% FBS in 1x PBS pH 7. 
 
AutoMACS buffer  
0.5% BSA and 2mM EDTA in 1x PBS pH7.2. 
Staining buffer for flow cytometric analysis 
 1% FBS and sodium azide in 1x PBS 
Extraction buffer  








Washing buffer   
1x PBS and 0.05% Tween-20, pH 7.2-7.4. 
Blocking buffer for total IgA 
2% BSA in 1x PBS pH 7.2-7.4 
Blocking buffer for anti-Salmonella IgA 
5g sucrose, 0.05g sodium azide and 1g BSA in 100ml 1x PBS pH 7.2-7.4 
Reagent diluent for anti-Salmonella and total IgA 
1% BSA in 1x PBS, pH 7.2-7.4 
 
HBSS  
0.4g KCl, 0.09g Na2HPO4.7H2O, 0.06g KH2PO4, 0.35g NaHCO3, 0.14g CaCl2, 0.1g 
MgCl2.6H2O, 0.1 MgSO4.7H2O, 8g NaCl and 1g D-glucose in 1L distilled water, adjust 
















Conjugate Catalog # Company  Dilution  
CD19 PE 12-0192 e-Bioscience 1/100 
Sca-1 Biotin 01162D Pharmingen 1/100 
F4/80 PE 8-12-4801-82 e-Bioscience 1/100 
F4/80 FITC 114801 e-Bioscience 1/100 
CD11b PE 01715A Pharmingen 1/200 
CD11b FITC 17146 Pharmingen 1/100 
Gr-1 Biotin 553125 Pharmingen 1/500 
Streptavidin PE 12431287 e-Bioscience 1/100 
Streptavidin FITC 11431187 e-Bioscience 1/100 
CD3e FITC 100306 Biolegend 1/100 
CD4 PE 12-0041-83 e-Bioscience 1/500 
CD4 APC 17-0041-82 e-Bioscience 1/200 
CD4 PE/Cy7 100528 biolegend 1/200 
CD8a APC 17-0081-82 e-Bioscience 1/200 
CD8a APC/Cy7 557654 BD pharmingen 1/100 
CD11b APC/Cy7 557657 BD pharmingen 1/400 
CD11c PE 12-0114-82 e-Bioscience 1/100 
CD19 PE 557399 e-Bbioscience 1/200 
CD19 PECy7 552854 BDpharmingen 1/200 
F4/80 PE/Cy7 25-4801-82 e-Bioscience 1/100 
MHC Class II (I-
A/I-E) 
APC 17-5321-82 e-Bioscience 1/500 





 Continue Summary of antibodies used for flow cytometry  
Antibody (all 
anti-mouse) 
Conjugate Catalog # Company  Dilution  
     
CD25 APC-eFluor® 
780 
47-0251-82 e-Bioscience 1/200 
CD25 APC 557192 BD pharmingen 1/100 
Sca-1 FITC 553335 BD pharmingen 1/200 
Sca-1 PE 553336 BD pharmingen 1/100 
Ly-6A/E (Sca-1) PE-Cy7 25-5981-82 e-Bioscience 1/200 
Ly-6A/E (Sca-1) APC 17-5981-83 e-Bioscience 1/100 
CD80 (B7-1) APC 560016 BD pharmingen 1/200 
CD80 (B7-1) PE 12-0801-83 e-Bioscience 1/100 




00-6993-50 e-Bioscience 1/100 
CD40 FITC 1645-02 SBA 1/100 
CD16/32 Fc receptor 
blocker 
























Elisa kits   
Mouse IL-2  R&D DY402 
Mouse IL-4  
 
BD pharmingen 555232 
Mouse IL-6  BD pharmingen 555240 
Mouse IL-10  BD pharmingen 555252 
Mouse IL-12  BD pharmingen 555165 
Mouse IFN-γ  BD pharmingen 555138 




CD11b MACS Milteni Biotec 130-049-601 
AutoMACS Running Buffer  MACS Milteni Biotec 130-091-221 
AutoMACS Rinsing Buffer  MACS Milteni Biotec 130-091-222 
   
Vybrant. Phagocytosis Assay 
Kit containing fluorescein-
labeled E.coli (K-12 strain) 
Invitrogen V6694 
BD Cytofix/Cytoperm Plus BD pharmingen 555028 
Goat anti-IgA antibody-biotin Southern Biotech 1040-08 
Goat anti-mouse 
IgM+IgG+IgA (H+L) 






4.1.5 List of chemicals and enzymes 
 
Chemicals Company Catalog # 
Paraoxon ethyl Sigma  36186 
DTNB Sigma D-8130 
Ethoprorazine Sigma E-2880 
Acetylthiocholine Sigma  A-5751 
Sodium nitrite Sigma  237213 
Phosphoric acid  Sigma  P5811 
Sulfanilamide Sigma  S-9251 
Naphthylethylene diamine 
hydrochloride 
ICN Biochemicals 152549 
Acetone Panreac 131007.1212 
Trypan blue Sigma  T-8154 
Evans blue dye Sigma  E-2129 
Tween-20 Sigma  P-7049 
Tetramethylbenzidine TMB BD 51-2607 KC 
Sulphuric acid Reidel-de-Haen 339741 
Salmonella-shigella  (SS) agar MAST DM205D 




Ampicillin Sigma  A9393 
7.5% sodium bicarbonate Hyclone SH30033.01 
Paraformaldehyde Sigma  P-6148 
Bovine serum albumin Sigma  A-2153 
EDTA Promega H5032 
Strepavidin-HRP R&D Systems DY998 
Streptomycin Sulfate Salt Sigma  S-0130 
Isoflurane Baxter 1087151 
Collagenase  Sigma C-2674 




4.1.6 List of tissue culture reagents 
 
Tissue culture reagents Company 
Catalog # 
ConA  (Concanavalin A ) Pharmacia 17-0450-01 
LPS ( Lipopolysaccharide from S. 
typhimurium) 
Sigma L-6511 
RPMI Hyclone SH.30027.01 
FBS (fetal bovine serum) Hyclone SV30173.08 
L-glutamine Gibco BRL, Paisley, UK  21051-024 
Sodium pyruvate Gibco BRL, Paisley, UK  11360-088 
Sodium bicarbonate Hyclone SH30173.08 
Essential amino acids 
 
Gibco BRL 418615 
Non-essential amino acids Gibco BRL 11140-035 




2-ME  Sigma 14997 










4.1.7 List of RNA-PCR reagents 
 
RNA-PCR reagents Company 
Catalog # 
Trizol Invitrogen 15596-026 
Chlorophorm Analytical UNIVAR 
Reagents 
152 
2-propanol ALDRICH 19516 
Ethanol CARLO EBRA Reagents 64-17-5 
TaqMan reverse transcription reagent Applied Biosystems N8080243 
2xTaqMan Universal Master Mix Applied Biosystems/ 
MetaBion 
4352042 
20x TaqMan assay Mix Applied Biosystems 4331182 














4.2.1 Paraoxon preparation  
Paraoxon ethyl (Sigma Chemicals Co., St Louis, MO) stock solution was prepared at a 
concentration of 10 mmol/L in anhydrous acetone.  Working solution for intraperitoneal 
(i.p.) administration was prepared ex tempore in 1x PBS to a final concentration of 80 
nmol/ml.  Each mouse received 40 nmol/0.5ml/day of paraoxon (equivalent to 0.44 
mg/kg of body weight) by intraperitoneal injection. Control animals received an 
equivalent volume of 1x PBS (0.5 ml). All injections were given i.p. daily for 5 
consecutive days, followed by a 2-day rest, and this cycle was repeated for a total of 3 
weeks.    
4.2.2 Experimental protocol 
Male BALB/c male mice of matched age and weight were randomly assigned into two 
groups: 
1. Control animals  were treated daily with i.p. injection of pyrogen-free saline for 
3 weeks 
2. Experimental group received daily injection of  40 nmols of paraoxon for 3 
weeks 
Mice were weighed weekly and blood was also collected and analyzed for acetyl 
cholinesterase (AChE) activity. At the end of the third week of treatments, animals were 
either sacrificed for the collection of different internal organs, or infected with one of the 
two strain of S. Typhimurium  (BRD509 (115) or SL1344 (43)) and sacrificed at 
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indicated time points. Serum from every sacrificed mouse was obtained and stored 
frozen at -20
o
C until further analysis.  
4.2.3 Red blood cells AChE activity 
Venous blood was collected from the tail (20µl), diluted in 2ml of 0.1 M phosphate 
buffer and stored at -20
ο
C (for not more than 2 months) until analyzed. After thawing, 
1ml of the sample was incubated with 2ml of phosphate buffer, 100µl of 10 mM DTNB 
(5,5’-dithiobis-2-nitrobenzoic acid) and 10µl of 6 mM ethoprorazine for 20 minutes 
in a water bath set at 37
o
C. Then, 50µl of the substrate, 28.4 mmol/L acetylthiocholine, 
was added immediately before measuring the absorbance. The change in the absorbance 
of the DTNB was measured at 436 nm using Du-70 spectrophotometer (Beckman 
coulter Inc. Pasadena, CA, USA). To measure the total hemoglobin (Hb) content, 1ml of 
the blood sample was incubated with 1ml of transformation buffer for 10 minutes at 
room temperature. Then absorption at 546nm was read against water blank. AChE 
activity was calculated using the absorbance coefficient of TNB
-





). Values were normalized to the Hb content (determined as 
cyanmethemoglobin) and expressed as mU/µM/HB (116). All enzyme activity was 







4.2.4 Spleen and mesenteric lymph nodes (MLN) cell preparation   
After the aseptic removal of spleen and MLN, organs were gently teased in 1x PBS 
using the frosted ends of microscopic slides in order to get single cell suspensions. Cells 
were spun at 1200 rpm for 5 minutes at 4
ο
C and re- suspended in cold 1x PBS. In order 
to lyse the RBCs, spleen cells were incubated with cold RBCs lysis buffer (10 
ml/spleen) for 3 minutes. Then, cells were spun at 1,200 rpm for 5 minutes at 4
ο
C and 
washed with 5 ml cold 1x PBS, spun and re-suspended in 1x PBS. Cells were, then, 
counted on a hemocytometer and cell viability was determined by trypan blue dye 
exclusion method.   
4.2.5 Isolation of peritoneal cells 
Peritoneal exudate cells (PECs) were retrieved by peritoneal lavage. Briefly, peritoneal 




 free) and centrifuged at 
1200 rpm for 5 minutes at 4
ο
C. Cells were re-suspended in 1ml cold 1x PBS and 
counted using hemocytometer. Cell viability was determined by trypan blue dye 
exclusion method. If required, 300µl were kept for bacterial load determination.  
4.2.6 Cellular ex-vivo culture  
Erythrocyte-depleted splenocytes and PECs single cell suspensions were prepared in 




cells/ml) were cultured, 
in 24-well plates, in the absence or presence of ConA (2.5-5µg/ml) or LPS (10 µg/ml). 
PECs (1.5x10
6
 cell/0.5ml) were cultured in the absence or presence of LPS at 10µg/ml 
concentration, in 24-well plates. Then, cells were incubated for 24 - 48 hours at 37
o
C in 
5% CO2. Culture supernatants were collected spun free of any cells and kept at -20
o
C 
until assayed for cytokines and nitric oxide content.  
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4.2.7 Nitric oxide determination  
Production of nitric oxide (NO) was measured by detecting levels of nitrite (NO2
-
), a 
stable metabolite of the reaction of NO with oxygen, according to the Griess method. 
The nitrite concentration was determined from a standard curve prepared using sodium 
nitrite (5-100 µM), 5 µM being the minimum limit of detection. Standard curve was 
prepared from 100mM sodium nitrite stock solution by 1-fold serial dilution. In 96-well 
plates, 50µl of the standard or samples were added to the wells, in duplicates. 
Subsequently, 50µl of Griess reagent were added to each well. Color was developed 
within 5 minutes and absorbance measured at λ= 492 nm using a Sunrise TECAN 
microplate reader (Maennedorf, Switzerland) 
4.2.8 Cytokine analysis 
Supernatants of ex-vivo-cultured cells and serum samples were analyzed for cytokine 
content using BD OptEIA ELISA mouse kit (BD, Franklin Lakes, NJ, USA) and Duoset 
ELISA development kits (R&D, Minneapolis, MN, USA). All cytokine determinations 
were carried out in non-adherent 96-well plates (Nunc, Roskilde, Denmark). Plates were 
coated overnight with 100µl/well of capture antibody diluted in 0.1M sodium 
carbonate coating buffer or 0.2M sodium phosphate coating buffer at 4
o
C. After 
overnight incubation, plates were washed with washing buffer and then blocked with 
assay diluent (250µl/well) for 1 hour at room temperature. Afterwards, plates were 
washed, standards were diluted in assay diluent to appropriate dilutions to make the 
standard curve, and samples were added in the appropriate dilutions. Standards and 
samples were added in a total volume of 100µl/well and incubated for 2 hours at room 
temperature. After washing, plates were incubated with 100µl of the detection antibody 
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and streptavidin-horseradish peroxidase conjugate (SAv-HRP reagent) for 1 hour in the 
dark at room temperature. Plates were, then, washed and 100µl of Tetramethylbenzidine 
(TMB) substrate solution was added. After 10-30 minutes, the reaction was stopped by 
2N sulphuric acid and absorbance was measured at λ=450nm by TECAN microplate 
reader (Maennedorf, Switzerland). Magellan3 software (TECAN) was used to calculate 
the results. The sensitivity of detection was 30pg/ml for IFN-γ and IL-10, 15pg/ml for 
IL-6 and IL-12/IL-23p40. 
4.2.9 Bacterial strains and preparation  
Two strains of Salmonella enterica serovar Typhimurium (S. typhimurium) were used in 
this study: the wild-type virulent strain SL1344 and the attenuated double auxotrophic 
strain aroA/aroD mutant designated BRD509E (115). Due to deletions in the aroA and 
aroD genes, BRD509E strain lacks the ability to produce essential prokaryotic aromatic 
compounds which makes its growth weak and slow. Additionally, SL1344:lux, a 
bioluminescent bacterium tagged by expression of the lux operon from Photorhabdus 
luminescens was generously provided by Prof. Christopher H. Contag, (Stanford 
University School of Medicine, Stanford, California). 
To grow the bacteria, thawing aliquots of frozen bacteria stock were plated on 
Salmonella Shigella (SS) agar plates with (BRD509E) or without (SL1344) ampicillin 
(100µg/ml). For bacterial dosage preparation, three to five colony-forming units (CFU) 
were cultured in 10 ml of tripticase soy broth (TSB) with (BRD509E) or without 
(SL1344) ampicillin (1µg/ml) overnight and then diluted 1:5 in fresh TSB with 
(BRD509E) or without (SL1344) ampicillin (1µg/ml) and grown for two hours shaking 
at 200rpm and 37
o
C. To determine bacterial concentration, 1 ml of the culture was read 
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on a spectrophotometer at λ=600 against TSB as blank. Appropriate dilutions of the log-
phase bacterial suspension were made in pyrogen-free 1x PBS to prepare the indicated 
doses and their verification. Bacterial dose was confirmed by CFUs plate counts. For 
systemic infection, 0.5ml/mouse of BRD509E at the indicated dose was injected 
intraperitoneally (i.p.). For oral inoculation, 200µl of 7.5% sodium bicarbonates were 
given 5 minutes prior to the administration of SL1344 (200 µl) in order to neutralize the 
stomach acid. Gavage needles (CADENCE science, Staunton, VA, USA) were used for 
the administration of sodium bicarbonate and SL1344.  
4.2.10 Determination of bacterial load in organ homogenates and fecal pellets  
Fecal pellets were freshly collected from infected animals at different time points, 
weighed and homogenized in 0.5 – 1 ml cold 1x PBS. Then, 50-100 µl from the 
homogenate or appropriate dilution were plated on SS agar plates with Streptomycin 
(200 µl/ml) for the pellet collected from SL1344 infected animals, or Streptomycin (200 
µl/ml) and ampicillin (100 µl/ml) for the pellet collected from BRD509E infected mice. 
CFUs counts were determined after overnight incubation at 37°C. 
Mice were sacrificed at different time points after i.p. or oral infection. Spleen, liver and 
mesenteric lymph node (MLN) were aseptically removed at indicated time points and 
homogenized in 1-2 ml cold 1x PBS in an Ultra-turrax T-25 tissue homogenizer (Janke 
& Kunkle, Staufenim Breisgau, Germany). 100 µl aliquot of the homogenate or 
appropriate dilution were plated on SS agar with (BRD509E) or without (SL1344) 




To determine the bacterial loads in the freshly collected peritoneal fluid, 100 µl were 
plated following the same above described protocol. 
4.2.11 In vivo Bioluminescence Imaging (BLI) 
Mice treated with paraoxon or saline for three weeks were infected by oral gavage with 
SL1344::lux (1x10
5
 CFUs/200µl/mouse). Five minutes previous to the infection, 200 µl 
of 7.5% sodium bicarbonate were administered to the animals by oral gavage. Bacterial 
dissemination and, therefore, progression of the disease was followed by in vivo 
bioluminescence imaging (BLI) using in-vivo imaging system (IVIS) Lumina II (Caliper 
Life Sciences, Hopkinton, Massachusetts, USA). 
Mice were initially placed in a chamber where they inhaled a mixture of the anesthetic 
isoflurane (Baxter, Deerfield, IL, USA) and oxygen. Afterwards, mice were moved to 
the platform in the imaging chamber where their noses were put at the anesthetic-gas 
ports to maintain anesthesia. At different time points, mice were imaged for 8 minutes to 
detect the light emitted by the bioluminescence bacteria which is transmitted through the 
mouse tissues. Data acquisition and analysis were performed using living image 
software (Caliper Life Sciences). 
4.2.12 Splenic macrophages purification 
Splenocytes were magnetically labeled to mouse microbeads conjugated with 
monoclonal anti-mouse CD11b antibodies (MACS Milteni Biotec). Cells were labeled 
using 10µl of the beads per 1x10
7
 cells and incubated at 4
o
C for 15 minutes. Then, cells 
were washed with 1-2 ml/10
7
cells of AutoMACS buffer and spun for 10 minutes at 4
 
o
C at 1500rpm. Afterwards, cells were re-suspended in 500µl of AutoMACS buffer and 
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positively selected by magnetic separation using the autoMACS separator (MACS 
Miltenyl Biotec, Bergisch Gladbach, Germany). Flow cytometric analysis of purified 
cells showed an approximate of 80-90% purity.  
4.2.13 Flow cytometry 
Cells, at a concentration of 0.5x10
6
 cells/well, were incubated in U shaped bottom 96-




in 50µl of staining buffer containing anti-
CD16/CD32 monoclonal antibody (clone 2.4G2) to block the FcyII/III receptors to 
prevent any non-specific binding of the antibodies. Then, the plate was spun at 750rpm 
for 3 minutes at 4
ο
C, decanted and cell incubated with different combinations of 
conjugated monoclonal antibodies (from BD or Biolegend or eBioscience as detailed in 
table.1) in a total volume of 100µl/well. 7-AAD (7-amino-actinomycin D) (eBioscience, 
San Diego, CA, USA), a fluorescent DNA intercalator, was used with each combination 
for exclusion of non-viable cells. For each antibody, appropriate isotype control was 
used. All antibodies were titrated in preliminary experiments and used at saturating 
concentrations. After 30 minutes of incubation at 4
ο
, plates were spun, decanted and 
cells washed twice with staining buffer. In the first wash, 100µl/well of staining buffer 
was added to the cells that were then mixed, centrifuge and decanted. In the second 
wash, 200µl/well of staining buffer was added to each well, where cells were mixed, the 
plate, then, was centrifuge, decanted and cells were re-suspended in 500 µl of staining 
buffer.
 
Cells were read immediately or fixed overnight by adding 100 µl of 4% 
paraformaldehyde. Data were collected on 30,000 cells using BD FACS Canto II (BD 




For the earlier experiments, single spleen cell suspensions and peritoneal cavity cells 
were stained with only two fluorescent conjugated monoclonal antibodies. Spleen cells 
were double stained with different combinations of directly conjugated monoclonal 
antibodies specific to: CD19 and CD3, Gr-1 and CD11b, CD3 and Sca-1, CD19 and 
Sca-1. Peritoneal cells were labeled with following combinations of directly conjugated 
monoclonal antibodies specific to: F4/80 and CD11b, F4/80 and Sca-1. Cells were 
analyzed by FACScan (BD). Data were collected on 20,000 cells and analyzed by 
CELLQUEST software (BD). 
4.2.14 Intracellular staining 
For intracellular staining, 2x10
6
/ml/well splenocytes were seeded in 24-well plate and 
stimulated them with PMA (100ng/ml) and ionomycin (1mg/ml) along with 1µl of BD 
GolgiPlug (Berfeldin A) for 4 hours at 37
o
C in 5% CO2 incubator. Un-stimulated cells 
were cultured without PMA/ionomycin to serve as a negative control. Cells were then 
incubated with blocking buffer for 30 minutes at 4°C before stained for surface markers 
CD4 and CD8 as mentioned earlier. After that cells were permeabilized using 100µl 
permeabilization/fixation buffer (BD Cytofix/Cytoperm Plus) for 20 minutes at 4°C. 
Cells were washed twice with 200µl 1x permeabilization buffer and then stained with 
100µl of anti-mouse IFN-γ antibody conjugate for 30 minutes at 4°C. Cells were washed 
with 200µl permeabilization buffer and re-suspended in 300µl permeabilization buffer. 
Data acquisition was done on 30,000 cells using BD FACSDiva software.    
4.2.15 Collection of fecal samples for the estimation of fecal IgA 
Mice pre-treated with saline or paraoxon, were infected i.p. with BRD509E bacteria and 
sacrificed at different time points. Fecal pellets were freshly collected, weighed and 
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suspended in extraction buffer (400µl of extraction buffer per 100mg of feces). The 
suspension was homogenized in extraction buffer. Each 100 mg of feces pellet was 
homogenized in 400µl of extraction buffer and then samples were placed on ice for 1.5-
2 hours. Afterwards, the homogenates were centrifuged at 10,000 rpm for 10 minutes at 
4
o
C. Supernatants were collected and stored at -20
 ο
C until they were analyzed for total 
or anti-Salmonella IgA antibody levels by ELISA.  
4.2.16 Estimation of fecal IgA by ELISA 
MaxiSorp 96-well plates (Nunc) were coated with 100µl/well of goat anti-mouse Ig 
H+L [IgA, IgG and IgM] antibody diluted in 1xPBS (0.1µg/ml) (Southern Biotech, 
Birmingham, AL, USA)  and incubated overnight at 4
o
C for total IgA. For detection of 
anti-Salmonella IgA plates were coated with 100µl/well of heat killed Salmonella 
diluted in 1xPBS (1x10
6 
CFUs/ml) and incubated overnight at room temperature. For 
both assays (total IgA and anti-Salmonella IgA), the rest of the protocol remains 
identical. Next day, plates were washed with washing buffer and blocked with 
300µl/well blocking buffer for 2 hour at room temperature. After washing, serial 
dilutions of test samples were prepared in individual Eppendorf tubes and 100µl aliquots 
transferred to the respective wells and incubated for 2 hours at room temperature. 
Afterwards plates were washed and incubated with 100µl/well of biotin conjugated anti-
mouse IgA antibody (Southern Biotech), diluted in reagent diluent for 2 hours at room 
temperature. After further washing, plates were incubated with 100µl of streptavidin-
HRP (R&D) for 40 minutes in dark at room temperature. Finally, color was developed 
by adding 100µl of TMB substrate solution for 10-15 minutes and the reaction was 
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stopped with 2N sulphuric acid (H2SO4). Plates were read with the TECAN microplate 
reader at λ=450nm. 
4.2.17 Intestinal transit  
Mice, treated with paraoxon or saline for three weeks, were fasted overnight 2 days after 
the last injection. The following day, mice received 100 µl of 5% Evans blue suspension 
by oral gavage. 15 minutes later, animals were sacrificed by cervical dislocation and the 
small intestine was removed and spread on a flat surface.  The distance travelled by the 
Evan blue dye was measured in centimeters and calculated as a percentage of the total 
length of the small intestine from duodenum to cecum. 
4.2.18 Isolation of intestinal epithelial cells 
Mice were treated with paraoxon or saline for three weeks.  Two days after the last 
injection, mice were fasted overnight. The following day, mice were sacrificed, their 
abdomen was opened and the small intestine immediately removed. Ileum (distal part of 
the small intestine) was separated from the rest of the intestine, cut into small pieces, 
opened and washed with 1x PBS. Intestinal pieces were, then, immersed in 3 ml of 
30mM EDTA in 1x PBS and shacked at 4
 ο
C for 45 minutes. Afterwards, samples were 
spun at 3,000 rpm at 4
ο
C for 10 minutes, supernatants aspirated and pellet incubated 
with 250µg of collagenase (Sigma, St. Louis, MO, USA) in 5ml HBSS at 37
 ο 
C for 10 
minutes with gentle shaking. After incubation, tissue debris was removed with a pipette 
and cells washed with 3 ml of HBSS and re-suspended in 1ml Trizol for RNA extraction 





4.2.19 Phagocytosis assay 
Phagocytic capability of purified splenic macrophages (CD11b
+
 cells) was measured 
using Vybrant Phagocytosis Assay Kit (Invitrogen, Life Technologies, Carlsbad, CA, 
USA) which contains Fluorescein-labeled Eschirichia coli K-12 BioParticles. 
Fluorescent E. coli Bioparticle suspension was prepared as per the manufacturer’s 
protocol instructions. One vial of BioParticles (5mg of solid powder) was thawed, 
suspended in 0.5 ml of 10x Hanks’ balanced salt solution (HBSS) and briefly sonicated. 
Suspension was, then, transferred to a glass tube containing 4.5 mL of deionized water 
and sonicated until all the fluorescent particles were homogeneously dispersed. 
Previously purified CD11b
+
 spleen cells (1x10
5
/50 µl/well, in DMEM) were added to 
96-well tissue culture plate and spun at 750 rpm for 3 minutes at 4
 ο
C. Supernatants were 
removed by vacuum aspiration and the adherent cells were incubated with 100µl of the 
prepared fluorescent BioParticles suspension. After 2 hours incubation at 37
ο
C in 5% 
CO2, supernatants were vacuum aspirated and 100µl/well of trypan blue was added and 
kept for 1 minute at room temperature to quench the extracellular fluorescence. Trypan 
blue suspension was then removed by vacuum aspiration. Intracellular uptake was 
quantified by measuring fluorescence emitted by engulfed bacteria at 485nm excitation 
and 535nm emission using a Victor X3 2030 microplate reader (PerkinElmer, Waltham, 
MA, USA). To minimize the effect of experimental errors, measurements of negative 
control, positive control and experimental samples were made in 4 replicates and the 
averages of these replicates were used for the calculations. Results were expressed as 
fold increase from the control mice. 
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4.2.20 RNA extraction using Trizol  
RNA was extracted from whole spleen cells or ileum epithelial cells using the Trizol 
method. Cells (2-5x10
6 
per sample) were pelleted and re-suspended in 0.5-1ml Trizol 
(Invitrogen) and stored at -80
ο
C. Afterwards samples were thawed and 200 l of 
chlorophorm were added to the vials and mixed well. Cells were then spun down at 
14,000 rpm for 10 minutes and of the 3 phases obtained, the top clear RNA layer (  
500µl) was transferred to a new tube. Equal volume of 2-propanol (  500 l) was then 
added and mixed well to precipitate the RNA. Tubes were spun, supernatants were 
discarded and washed with 500µl of 70% ethanol were added. On flicking the tubes, 
RNA was observed as a white pellet. Tubes were spun again, supernatant was removed, 
dried and RNA suspended in 20-50µl nuclease free water. Quality and quantity of the 
RNA was determined using the Nanodrop ND-1000 spectrophotometer (Thermo 
Scientific, Waltham, MA) and then, stored at -80°C. 
4.2.21 Reverse Transcription Reaction 
RNA was reverse transcribed using TaqMan reverse transcription reagent (Applied 
Biosystems, CA, USA). Each master mix reaction contained 10x RT buffer, 25mM 
MgCl2, deoxy NTPs mixture (2.5mM), random hexamers (50µM), RNAase inhibitor 
(20U/µl) and MultiScribe RT enzyme (50U/µl). The master mix was added into separate 
PCR tubes (Extragene, Palos Heights, IL, USA), RNA was added (1µg per reaction) and 
total volume was made up to 50µl with nuclease-free water. The one step RT-PCR 
reaction was run on GeneAmp PCR System 2700 from Applied Biosystems, under the 
following conditions: hexamer incubation for 10 minutes at 25°C, reverse transcription 
at 48°C for 30 minutes and reverse transcriptase inactivation at 95°C for 5 minutes. The 
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samples were held at 4°C for a maximum of 1 hour through which the samples could be 
removed and stored at -20°C. 
4.2.22 Real time PCR reactions 
The real time PCR was performed using TaqMan gene expression assay and amplified 
using the 7500 Real Time PCR System (Applied Biosystems). Each 20µl PCR reaction 
contained 10µl of 2xTaqMan Universal Master Mix, 1µl of 20x TaqMan assay Mix 
(both from Applied Biosystems), 2µl cDNA and 7µl nuclease free water. A negative 
PCR reaction was also carried out using only the reaction mixture without cDNA in 
order to ensure that there was no DNA contamination. The thermal cycling conditions 
were as follows: 95°C for 10 minutes (Inactivation of Reverse Transcriptase and 
activation of TaqMan polymerase), 95°C for 15 seconds (denaturation of dsDNA) and 
60°C for 1 minute (annealing/extension- fluorescent data collected during this step) for a 
total of 40 cycles with the threshold set as 0.2. Data was analyzed using the Ct values for 
each sample that were in duplicates. Results were normalized to HPRT (Hypoxanthine-
guanine phosphoribosyl transferase) and the mRNA fold change was determined using 
the following equation: 
Fold change= 2 
ΔCt (treated)
 / 2  
ΔCt (control)
, where  Δ Ct (treated) = threshold cycle (Ct) for 
target gene after treatment - Ct for HPRT after treatment and  Δ Ct (control) = Ct for 
target gene saline - Ct for HPRT saline.  
The assay IDs of the primers (Applied BioSystem, MA, USA) used are:  
 HPRT (Mm01545399_m1) 
 IL-12p40 (Mm00434174_m1) 
 IFN-γ (Mm01168134_m1) 
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 List of encoding sequences for AMPs primers (Metabion, Stciukirohen, 4.2.22.1
Germany)  
 
Gene Sequence 5’-3’ 
Defa1 forward CCGTATCTGTCTCCTTTG 
Defa1 reverse CGACAGCAGAGCGTGTA 
Defa1 probe FAM-AATGGAACCTGCAGAAAGGGTCATT-BHQ1 
Defa4 forward CCAAGAAGGGTCTGCTCT 
Defa4 reverse GCGGGGGCAGCAGTA 
Defa4 probe FAM-AGTTCGTGGGACTTGTGGAATACGAT-BHQ1 
CRS4C forward CAGGCTGTGTCTGTCTCTTT 
CRS4C reverse TTTGGATTGCATTTGCACCTC 
CRS4C probe FAM-CGTCATGCCCATCTTGCCCGAGA-BHQ1 
CRS1C forward CAGAAGGCTCTGCTCTTCA 
CRS1C reverse GCCTTTCTTCGCACAATGG 
CRS1C probe FAM-AAGTGCCAAGTGTGCCAGAAGTGC-BHQ1 
MMP-7 forward CACTGAACTTCAAGAGGGT 
MMP-7 reverse CATCCTTGTCAAAGTGAGC 
MMP-7 probe FAM-AACACTCTAGGTCATGCCTTCGCA-BHQ1 
Reg3 gamma forward TGGATTGGGCTCCATGAC 
Reg3 gamma reverse TGAGGCTCTTGACAGGG 
Reg3 gamma probe FAM-ACGAATCCTTCCTCTTCCTCAGGC—BHQ1 
Ang4 forward CTTGACACCGAAGGACC 
Ang4 reverse TCACAACCAGACCCAGCA 
Ang4 probe FAM-AGCCCATGTCCTTTGTTGTTGGTCT-BHQ1 
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4.2.23 Light microscopy analysis of the ileum  
The distal part of the intestine (ileum) was removed and immediately fixed in 10% 
formalin. After overnight fixation, tissues were placed in histological cassettes, 
dehydrated in ascending series of graded ethanol cleared with xylene and then infiltrated 
and embedded in paraffin (Sherwood Medical, St. Louis, Mo, USA). Blocks were 
trimmed and 5 µm sections cut in a Shandon Finesse 325 manual microtome (Thermo 
Scientific, Pittsburg, PA, USA) and placed on gelatin coated slides. Sections were then 
rehydrated in xylene, descending series of graded ethanol and distilled water and then 
stained with Instant Haematoxylin  (Thermo Scientific Shandon, Pittsburg, PA, USA)  
for 10 minutes followed with eosin yellowish (Panreac, Spain) for 1 minute.  Finally, the 
sections were dehydrated in ascending series of graded ethanol, cleared in xylene and 
mounted with DPX (Panreac, Spain). Images were captured with an Olympus BX51 
microscope model V-LH100HG (Olympus Corporation, Japan).   
4.2.24 Electron microscopy analysis of the ileum 
The distal part of the intestine (ileum) was removed and immediately fixed in a mixture 
of 2.5% glutaraldehyde and 2% formaldehyde solution (pH=7.2 in phosphate buffer) 
overnight at 4°C. Samples were rinsed with 0.1 M phosphate buffer, post-fixed in 1% 
aqueous osmium tetroxide for 1 hour and then rinsed in distilled water. Afterward, 
samples were dehydrated in ascending series of graded ethanol, infiltrated with Agar100 
epoxy and finally embedded in the same resin where they polymerized at 65°C for 24 
hours. Blocks were trimmed, semithin (0.5mm) sections cut in an ultramicrotome Leica 
EM UC7 (Leica, Welzlar, Germany) and stained with1% aqueous toluidine blue on 
glass slides. After selecting the right blocks, ultrathin (95-100 nm) sections were 
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prepared on 200 mesh copper grids and contrasted with 2% uranyl acetate for 40 
minutes and lead citrate for an additional 25 minutes. Grids were then air dried on filter 
paper and the sections were examined and photographed with TENAI G2 Spirit 
Transmission Electron Microscope (FEI, Hillsboro, Oregon, USA). 
4.2.25 Statistical analysis  
Statistical significance was analyzed by Mann-Whitney test or unpaired two-tailed 
Student’s t-test or the log rank (Mantel-Cox) test for Kaplan-Meier functions (for 
survival analysis) using GraphPad Prism software (San Diego, CA, USA). Differences 














Chapter 5 : Results 
5.1 AChE activity in mice exposed to paraoxon 
In every experiment the effectiveness of the paraoxon as a potent AChE inhibitor, was 
confirmed by measuring the RBC AChE activity in blood. Blood from control and 
experimental animals was collected just before the treatment started and at the end of 
each of the three weeks that the treatment lasted. After one week of paraoxon treatment 
AChE enzymatic activity was reduced by 50% of baseline value. This reduction was 
maintained tell experiment was terminated (Fig. 1). In contrast, control group showed no 
significant changes in the enzyme activity, from the baseline, during the three weeks of 
treatment. Differences in AChE activity between the experimental and control groups 
were significant (p ≤ 0.001) at all time points, confirming that paraoxon treatment 










































Figure 1: Reduction of RBC AChE activity in paraoxon treated mice. 
Mice were treated with paraoxon or saline for three weeks. Enzyme activity was 
measured following modified Ellman’s method. All enzyme activities were 
expressed in percentage of the baseline activity (100%). Depicted are the mean 
values ± SD of data pooled from 4 independent experiments. Asterisks denote 
statistically significant differences between the control and experimental groups 
***p<0.001.   
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5.2 Effect of AChE inhibition on the mouse body weight 
Body weight change over the three week of treatment was also assessed. Body weights 
were recorded before starting the treatment with saline (control) or paraoxon and 
considered as a baseline. Mice were weighed once per week during the three weeks 
treatment and the percentage increase in body weight calculated. The results showed that 
the body weights of saline-treated animals gradually increased by 3.5% after the first 
week, 6.8% after the second week and 7.6% after the third week of treatment (Fig. 2). 
Paraoxon treated mice showed a 0.09% reduction in their weights after the first week of 
treatment. During the following week (week 2), mice experienced a modest increase in 
their body weight of 1.6% of their original weights. During the third week of the 







































Figure 2: Retarded growth of paraoxon-treated mice. 
Mice were treated with paraoxon or saline for three weeks. Weekly 
change in body weight was calculated as percentage of the initial 
weight. Depicted are the mean values ± SD of data pooled from 3 
independent experiments. Asterisks denote statistically significant 
differences between the control and experimental groups 
***p<0.001.   
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5.3 Response to a lethal oral infection after AChE inhibition 
After three weeks exposure to paraoxon or saline, mice were inoculated orally with 
SL1344, a virulent strain of S.Typhimurium at a lethal dose of 1x10
4 
CFUs/mouse. Mice 
were then followed for survival for up to day 60 post-infection. Results revealed that 
exposure to paraoxon enhanced the percentage survival, with 76.5% of the mice 
surviving the lethal infection and a median of >60 days, the maximum period of 
observation (Fig. 3). This was in sharp contrast to the saline-treated group where percent 
survival was only 24% with a median of 11 days. This difference on survival, between 







































Figure 3: Paraoxon-treatment enhanced host survival in a lethal oral 
infection. 
 Mice were treated with paraoxon or saline for three weeks. At the end of 
the treatment mice were infected orally with a dose of 1x10
4
 CFUs/mouse 
of SL1344 and followed for survival up to 60 days post infection. Depicted 
are the mean values ± SD of data pooled from 3 independent experiments. 
Asterisks denote statistically significant differences between the control 
and experimental groups **p<0.01. Chi squared (Mantel-Cox) statistical 
test was used for this analysis. 
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5.4 Effect of AChE inhibition on spleen, mesenteric lymph nodes and peritoneal 
exudate cells   
First, the effect of paraoxon treatment and, therefore, inhibition of the AChE activity on 
the lymphoid organs involved in the immune response to bacterial infection that could 
explain the resistance to infection of paraoxon-treated mice was evaluated. MLN and 
spleen were collected from paraoxon-treated mice and compared to the organs from the 
control group who received saline for the same period of time. Because paraoxon 















 Size and cellularity 5.4.1.1
Paraoxon pre-treatment did not show a significant impact on spleen weights. The 
average spleen size of paraoxon-treated mice was 117 ± 4.07 g compared to the control 
mice weight of 128 ± 5.7 g (Fig. 4A). No statistical differences were found between the 
groups.  Furthermore, when the spleen cellularity was calculated, paraoxon-treated 
group, as expected, showed a lower number of cells per spleen with an average of 
85x10
6 
± 5 cells/spleen while the control group rendered an average of 112x10
6 
± 11 



























































Figure 4: No change in spleen size and cellularity following 
paraoxon treatment. 
Mice were treated with Paraoxon or saline for three weeks. Then 
spleen weights (A) and spleen cell counts (B) were determined. 
Depicted are the mean values ± SD of data pooled from 2 
independent experiments.   
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 Spleen phenotyping and activation markers 5.4.1.2
Flow cytometric analysis of the different splenic cell populations and their activation 
status were evaluated per spleen after three weeks of treatment with saline or paraoxon. 
Regarding the spleen cell population in saline-treated mice, CD3
+
 cells (T cells) 
represented 33 ± 2.3%, CD19
+
 cells (B cells) were 43 ± 2.1%, CD11b
+
 cells (myeloid 
cells) were 11.4 ± 1.04% and CD11c
+
 cells (dendritic cells) were found to be 8.5 ± 
0.63% of the total spleen population (Fig. 5A and 5B). Paraoxon pre-treatment did not 
cause any significant alteration compared to the control mice in the percentages of the 
different spleen populations. The spleen of paraoxon-treated mice presented 33 ± 2.3% 
of CD3
+
 cells (T cells), 42 ± 0.59% of CD19
+
 cells (B cells), 12.5 ± 1.16% CD11b
+ 
cells 
(myeloid cells) and 9.5 ± 0.58% of CD11c
+
 cells (dendritic cells). When these 
percentages were used to calculate the total number of cells in each spleen population 
(Fig. 5C), no significant differences were found between the two groups. Due to the 
lower cellularity of the paraoxon-treated spleens, the total numbers of T (17.7 ± 1.7x10
6
) 
and B cells (22.9 ± 3.46x10
6
 ) were 18% lower than in spleens of control mice (21.5 ± 
0.35x10
6
 and  27.9 ±2.59x10
6







 (5.2 ± 1.01x10
6
) cells in paraoxon-treated mice decreased only 
6.8% and 5.5% compared with the saline treated group (7.4 ± 0.74x10
6 
and 5.5 ± 
0.58x10
6
, respectively) which could indicate a discrete increment in myeloid cells 















Figure 5: Flow cytometric analysis of total spleen population 
Mice were treated for three weeks with paraoxon or saline. Afterwards, 
erythrocyte-depleted spleen cells were analyzed by flow cytometry. 
Representative dot plots show the positive cell percentages in saline and 
paraoxon-treated mice (A). Bar graphs show percentage of positive cells 
(B) and absolute cell number (C). Graphs depicted the mean values ±SD 















Next, the splenic CD3
+




 were studied along 
with the expression of the activation markers CD25 and Sca-1. Figures 6A and 6B show 
representative dot-plots of gated CD3
+
 cells and the percentages of CD4 and CD8 
subpopulations in each group. In the control group, CD4
+
 T cells represented the 
majority of the cells (66.3 ± 1.2%) while CD8
+
 cells were 23.9 ± 1.2% of the total CD3
+
 
T cells (Fig. 6A). Paraoxon pre-treatment did not alter these percentages of CD4
+
 (66.5 
± 2.3%) or CD8
+
 (23.8 ± 1.6%)  T cells among the CD3
+
 cell population (Fig. 6B) 
compared to the saline-treated group. Figure 6C shows a bar graph represents the 




 T cells in each group. No differences 
between the control saline-treated and the paraoxon-treated animals were found. 




 cells in each group was also calculated 
(Fig. 6D) and showed no significant differences of both population, in both the 
paraoxon-treated animals and controls which correlates with the smaller spleen size and 


















T cells.  
In order to see whether paraoxon treatment modified the activation status of T cells, the 





were analyzed (Fig. 6 E-H). The expression of CD25 on CD4
+
 cells was only 1.3 fold 
higher in paraoxon group (19.6 ± 1%) compared to that in the saline group (14.9 ± 
1.4%) as seen in Fig. 6E. Similarly, 14.8 ± 1.9% of the CD4
+
 cells were positive for 
Sca1 activation marker in the control group, while in the experimental group these cells 
represented 17.5 ± 1.7% of the total CD4
+
 population (Fig. 6A). Based on these 
65 
 
percentages, the total number of cells in each population was calculated (Fig. 6F). 
Despite the fact that the total number of CD4
+
 cells was lower in the paraoxon treated 




 cells were higher (2.2 ± 
0.2x10
6
) in the experimental group compared to that in the control (1.9 ± 0.09x10
6
) (Fig. 




 cells was approximately identical (1.9 ± 0.06x10
6
 and 
1.96 ± 0.2 x10
6 
in the saline- and paraoxon-treated mice).  
Although the statistical differences between the groups were not significant, these 
results suggested a specific activation of CD4
+
 T cells in the spleen by the increase in 
the levels of ACh. 
The activation status of splenic CD8
+
 cells revealed that 92.2 ± 1.4% of the cells were 
positive for CD25 in the control group and 88.7 ± 1.7% in the experimental group. Sca1 
antigen was positive on 61.8 ± 2.2% and 63.6% in the control and paraoxon groups, 
respectively (Fig. 6G). When the total number of cells in each population was calculated 











 (2.5 ± 0.1x10
6
) cells than the saline-treated animals (4.4 ± 0.3x10
6
 and 
2.96  ± 0.3x10
6
, respectively). The differences between the different groups were found 




































Figure 6: Flow cytometric analysis of splenic T cells and their activation status. 
Mice were treated for three weeks with paraoxon or saline. Afterwards, 
erythrocyte-depleted spleen cells were analyzed by flow cytometry for changes in 
T cells subtypes and activation status. Representative dot plots show the positive 
cell percentages in saline (A) and paraoxon (B) treated mice. Bar graphs depicted 





 cell percentages (C), total number of CD4 and 
CD8/spleen (D), percentage (E), and total cell number (F) of CD4
+
 cells with two 
different activation markers and percentage (G), and total cell number (H) of 
CD8
+
 cells with two different activation markers.  
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To investigate the activation status of B cells (CD19
+
), three different surface activation 
markers were analyzed: CD80, CD86 and Sca-1. Fig.7A shows representative dot plots 
of Sca1, CD80 and CD86 staining in saline- and paraoxon-treated mice. Figure 7C 
shows the quantitative analysis of each marker comparing both groups. Only a minority 
of CD19
+
 cells were positive for these markers in both, control and experimental groups. 
While paraoxon treatment seemed to induce only a of 0.2% insignificant increase in 
CD80
+





 cells, respectively. These differences between the two groups disappeared when 
the total number of cells positive for each marker was calculated (Fig. 7D) due to the 






























Figure 7: Flow cytometric analysis of splenic B cells and their activation status. 
Mice were treated for three weeks with paraoxon or saline. Afterwards, 
erythrocyte-depleted spleen cells were analyzed by flow cytometry for changes in 
B cells activation status. Representative dot plots show positive cell percentages 
(A). Bar graphs depicted positive cell percentages (B) and cell number (C) of 
activation markers CD80, CD86 and Sca-1. Data are the mean values ±SD of 3 
mice/group from a representative experiment. Asterisks denote statistically 






















 cells were analyzed for their activation markers expression (CD40, 
CD80 and Sca-1). Figure 8A depicts representative dot plots from saline- and paraoxon-
treated mice. No significant differences were observed in the expression of any of the 
markers between the two groups as CD40
+
 cells were around 6% in both groups, CD80
+
 
cells 16.3 ± 0.8% in control and 18.1 ± 1.4% in paraoxon groups and Sca-1
+
 cells 6.9 ± 
0.4% in control and 7.9 ± 0.3% in paraoxon groups. These results were confirmed when 
the average percentages of each populations were plotted (Fig.8B). The total cell 
numbers in each population was calculated based on the percentages which showed 













































Figure 8: Flow cytometric analysis of splenic macrophages and their 
activation status. 
 Mice were treated for three weeks with paraoxon or saline. Afterwards, 
erythrocyte-depleted spleen cells were analyzed by flow cytometry for 
changes in macrophages activation status. Representative dot plots show 
positive cell percentages (A) and bar graphs show positive cell percentage 
(B) and positive cell number (C) of activation markers CD40, CD80 and 
Sca-1. Graphs depicted the mean values ±SD of 3 mice/group from a 
representative experiment.  
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 Macrophages phagocytic activity  5.4.1.3
Next, it was tested whether paraoxon treatment had any effect on the phagocytic activity 
of spleen macrophages. CD11b
+
 cells were purified from a single suspension of spleen 
cells from mice treated for three weeks with either saline or paraoxon. Enrichment of 
CD11b
+
 cells was verified by flow cytometry. Figure 9A shows dot plot representations 
of CD11b and Gr1 staining before and after purification in the control saline- and 
experimental paraoxon-treated mice. Spleen cells from control animals contained 11% 
of CD11b
+
 cells (from which 6% were Gr1
+
); in the experimental group, these cells 
represented 10% (out of which 5% were Gr1
+
) of the total spleen population. After 
purification, CD11b
+
 cells increased to 94% in the control and 92% in the experimental 
groups, which is an indication that there had been an 83% and 82% enrichment in the 




 after purification increased more than 10 
folds in both groups. 
Next, the phagocytic activity of the purified CD11b
+
 cells was assessed in both groups. 
The results showed a 3.5 fold increase in the phagocytic activity of CD11b
+
 cells from 
the paraoxon group compared with the ones from the control group. This difference in 






























Figure 9: Phagocytic activity of purified splenic CD11b
+
 cells. 
Mice were treated for three weeks with paraoxon or saline. Then, CD11b
+
 
spleen cells were purified from erythrocytes-depleted spleen cells by 
autoMACS. (A) Dot plot of flow cytometry represent the percent purity of 
purified cells, (B) fold increase in phagocytic activity of purified splenic 
CD11b
+
 cells. Graphs depicted the mean values ± SD of data from 2 
independent experiments. Asterisks denote statistically significant 
differences between control and experimental group * p<0.05. 
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 Gene expression of spleen cells 5.4.1.4
It was tested whether AChE inhibition modified the expression of IFN-γ and IL-12p40, 
the Th1 cytokines essential for a robust immune response to S. typhimurium infection. 
RNA from single cell suspensions of spleens from control and paraoxon-treated mice 
was extracted. cDNA was then prepared and analyzed for the expression of IFN-γ and 
IL-12p40.  
The relative expression of IFN-γ (Fig. 10A) was 0.024 ± 0.003 and 0.018 ± 0.0008 in 
spleen from control and experimental mice, respectively. Despite the fact that the 
reduction on IFN-γ expression in the experimental group was equivalent to 25%, this 
difference was not statistically significant. Figure 10B shows no differences in the 
relative expression of IL-12p40 between splenocytes from saline (0.0045 ± 0.0004) and 
paraoxon (0.004 ± 0.0004) treated mice.  








Figure 10: Gene expression profile in splenocytes. 
Mice were treated with paraoxon or saline for 3 weeks. Mice were sacrificed and 
spleens were collected. RNA was extracted from erythrocytes-depleted spleen 
cells, converted to cDNA and ran for real-time qPCR. Graphs depicted fold change 
in the mRNA relative expression of IFN-γ (A) and IL-12p40 (B). Mean values 















































 Cytokines production upon stimulation of spleen cells 5.4.1.5
Splenoctes cellular response to mitogenic activation was evaluated. Single cell 
suspensions of spleen cells were prepared from saline and paraoxon-treated animals and 
stimulated with LPS to activate macrophages or ConA which is a mitogen to T cells. 
After 24 hours, culture supernatants were collected and production of pro-inflammatory 
cytokines (IL-12p40, IFN-γ and IL-6) measured. After LPS stimulation, IL-12p40 and 
IL-6 cytokine levels were evaluated and compared to that in unstimulated cells. In the 
control group LPS stimulation induced a 1.7 fold increase in IL-12p40 production 
compared to that in the unstimulated cells. Similarly, LPS stimulated spleen cells from 
paraoxon-treated group produced 2-fold more IL12p40 than unstimulated cells (Fig. 
11A). When the production of IL-6 (Fig.11B) was analyzed, LPS stimulated spleen cells 
from both groups, showed an identical increase of 33.3 fold compared with that of the 
unstimulated cells. Production of IFN-γ was also analyzed after ConA stimulation of 
spleen cells. Figure 10C shows that ConA stimulated cells produced IFN-γ. In response 
to ConA stimulation, cells from paraoxon-treated mice produced 39% more IFN-γ than 
the cells from the control group. However, due to the different levels of IFN-γ 
production among the different members of the same group, the differences between 


























































Figure 11: Cytokines production from splenocytes after 24 hours in 
culture. 
Mice were treated for three weeks with paraoxon or saline. Then, 
erythrocytes-depleted spleen cells were cultured with or without 
stimulation for 24 hours. Supernatants were then assayed for the 
production of IL-12p40 (A) and IL-6 (B) before and after LPS (10 g/ml) 
stimulation. Production of IFN-γ (C) before and after ConA (2.5 g/ml) 
stimulation was also estimated. Graphs depicted the mean values ±SD of 

















 Intracellular staining of spleen T cells 5.4.1.6
A single cell suspension of splenocytes from paraoxon- and control-treated mice were 
cultured and stimulated with PMA/lonomycin for 4 hours. Cells were then stained for 
the surface molecules CD4 and CD8 and intracellularly for IFN-γ. Figure 12 represents 
dot plots of the flow cytometric analyses. Analysis of un-stimulated control cells showed 




 form the total spleen population were 8% and 
21%, respectively. Of these cells, 6% of the CD8
+
 and 1.3% of the CD4
+
 cells produced 
IFN-γ. In the control group, after stimulation, the percentages of T cells were 7.2 ± 
0.26% CD8
+
 cells and 23 ± 1.4% CD4
+
 cells while in the paraoxon-treated group, 11.6 ± 
0.5% of the cells were CD8
+
 and 26 ± 0.6% were CD4
+
. These represent a 7-fold (42 ± 
2.4%) and ~7.5-fold (45 ± 3.4%) increase of CD8
+
 cells in the control and experimental 
groups, respectively, after stimulation (Fig. 12). Percentages of CD4
+
 T cells that were 
positive for IFN-γ were 12% for both, control and experimental groups after stimulation 
(Fig. 12).  
The observed increase in the percentage of CD8
+
 cells in the paraoxon group after 
stimulation represented 57% more cells than in the control group (Fig.13A). However, 
no differences were found when the total number of cells was calculated, due to the 
lower cellularity of spleens in the paraoxon-treated animals (Fig. 13B). No significant 
differences were found, between saline- and paraoxon-treated groups, neither in the 





Our results indicate that paraoxon treatment did not induce an increase in the production 


















































































Mice were treated for three weeks with paraoxon or saline. Erythrocytes-
depleted splenocytes were cultured and stimulated with PMA/lonomicin for 4 
hours. Cells were then stained and analyzed by flow cytometry for surface 





, IFN-γ producing CD8
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Figure 13: Quantification of IFN-γ producing T cells from spleen. 
Erythrocytes-depleted splenocytes were cultured and stimulated with 
PMA/lonomicin. Cells were then stained for flow cytometry. Graphs show 
percentage (A) and absolute number (B) of CD4 and CD8 cells in the 
spleen of saline and paraoxon-treated mice. Graph C and D show 
percentage (C) and absolute cell number (D) of CD4 and CD8 IFN-γ 
producing cells. Graphs depicted the mean values ±SD of 3 mice/group of 
a representative experiment. Asterisks denote statistically significant 




5.4.2  Mesenteric lymph nodes 
 Size and cellularity 5.4.2.1
After 3 weeks treatment with saline or paraoxon, mice were sacrificed and mesenteric 
lymph nodes aseptically collected. Paraoxon treatment and therefore AChE inhibition 
did not have any influence on MLN weight (55 ± 5g in control mice and 58 ± 3.4g in 
paraoxon-treated) (Fig. 14A) or their cellularity (28 ± 4.6x10
6
 and 29 ± 3x10
6
in control 







 MLN phenotyping and activation markers 5.4.2.2
Single cell suspensions of MLN cells were prepared to evaluate whether paraoxon could 
have an effect on the number of the different cell populations or their activation status.  
First, we looked at the different cell populations present in the MLN of control animals. 
The flow cytometric analysis showed, as expected, that the majority of the cells  (63 ± 
1.4%) were CD3
+
 T cells, then 29 ± 2.7% CD19
+
 B cells, 5.9 ±1.3% CD11b
+
 and 4.1 ± 
0.4% CD11c
+
 (Fig. 15A & B). Paraoxon-treatment did not show any significant changes 















































Figure 14: No changes in MLN following paraoxon treatment. 
Mice were treated with Paraoxon or saline for three weeks. Then MLN 
weights (A) and cell counts (B) were determined. Depicted are the mean 
values ±SD of data pooled from 3 independent experiments.   
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cells were 66 ± 4.6%, CD19
+
 B cells 24 ± 2.9%, CD11b
+
 5.4 ± 1.5% and CD11c
+
 3.3 ± 
0.5% of the total MLN population (Fig. 15A & B). Similarly, when the total number of 
cells in each population was calculated no significant differences were found between 























































Figure 15: Flow cytometric analysis of MLN cell population. 
Mice were treated for three weeks with paraoxon or saline. Afterwards, MLN 
cells were analyzed by flow cytometry for changes in the total cell populations. 
Representative dot plots show positive cell percentages (A) and bar graphs show 
positive cell percentages (B) and cell numbers (C). Graphs depicted the mean 
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 (Fig. 16B). Similar 
percentages were observed in the CD4
+
 cells from the paraoxon-treated group (Fig. 
16F). No statistical differences were found between saline and paraoxon-treated groups 
in any of the above subpopulation of CD4
+
 cells (Fig. 17C). When the total cell number 






 cells from the experimental group 




 cells, the dot plots showed that saline and paraoxon-treated groups 




 cells (10 ± 6.8% vs 13 ± 4.4% 
respectively). The percentage of all Sca1
+
 cells was also similar in the two groups (86 ± 




 cells was 
54 ± 2.6% in saline group and 81 ± 1.2% in the paraoxon-treated group (Fig. 16D and 
H) which it was a difference statistically  significant (p≤0.01)  (Fig. 17E). When the 
total cell number of each population was calculated Sca1
+
 cells from the paraoxon group 


















Figure 16: Flow cytometric analysis of MLN T cells and their activation 
status. 
Mice were treated for three weeks with paraoxon or saline. Afterwards, 
MLN cells were analyzed by flow cytometry for changes in T cells subtypes 
and activation status. Representative dot plots show CD4
+
 (A and E), CD4 
activation markers (B and F), CD8
+
 (C and G) and CD8 activation markers 






















































































































































































































Figure 17: T cells population and their activation status in MLN 
Mice were treated for three weeks with paraoxon or saline. Afterwards, 
MLN cells were analyzed by flow cytometry for changes in T cells 
subtypes and activation status. Bar graphs depicted CD8 and CD4 positive 
cell percentages (A), cell number (B), CD4
+
 activation markers cell 
percentages (C), cell number (D), CD8
+
 activation markers percentages (E) 
and cell numbers (F). Graphs depicted the mean values ±SD of 2-3 
mice/group from a representative experiment. Asterisks denote statistically 




5.4.3  Peritoneal exudate cells 
 Cellularity 5.4.3.1
 
The fact that the administration of paraoxon and saline was intraperitoneal, it was 
interested to investigate whether these daily injections affected the cellular composition 
and functionality of peritoneal cavity cells.  
First, the peritoneal lavage cellularity was analyzed, as it was done previously the spleen 
and MLN. It was observed that paraoxon pre-treatment resulted in significantly lesser 
viable cell yield than the obtained in the control group as a total of 7.9 ± 0.9x10
6
 (1 ± 
0.1x10
6
/ml) cells were retrieved from paraoxon-treated mice and 12 ± 1x10
6
 (1.6 ± 
0.1x10
6






Figure 18: Decrease in peritoneal cavity cellularity following paraoxon 
treatment. 
Mice were treated with paraoxon or saline for three weeks. Then PECs 
were retrieved and total cell counts (A) and cell counts/ml (B) were 
determined. Depicted are the mean values ±SD of data pooled from 3 
independent experiments. Asterisks denote statistically significant 























































 PECs phenotyping and activation markers 5.4.3.2
After three weeks of treatment with saline or paraoxon, PECs were retrieved from the 
peritoneal cavity and cultured for 24 hours with or without LPS stimulation. Afterwards, 
cells were collected, stained and analyzed by flow cytometry for phenotyping and 
activation status of the different cell populations. Peritoneal exudates from unstimulated 













) cells (Fig. 19A and B) and 








Figure 19: Flow cytometric analysis of PECs after 24 hours in culture. 
Mice were treated with paraoxon or saline for three weeks. Then PECs 
were retrieved and culture for 24 hours. Phenotypic analysis of PECs is 
shown in representative dot plots (A) and bar graph (B) as percentage of 
positive cells. Depicted are the mean values ±SD of 3 mice/group from a 


































Representative dot plots for the analysis of the diverse activation markers on B1 and B2 
peritoneal cells were depicted on figure 20A. In the saline group, 10 ± 0.0005% of B2 
cells were CD40
+
 in un-stimulated PECs but after LPS stimulation 29 ± 5% of B2 cells 
were positive for CD40. In the paraoxon-treated group this population represented 23 ± 
1.8% (Fig. 20B). The differences between the control and experimental groups after LPS 
stimulation were statistically significant (p≤ 0.01). All the B2 cells in both groups were 
MHC II negative before and after stimulation. B1 cells positive for CD40, from saline-
treated mice, increased from 48 ± 1.5% on the unstimulated cells to 84 ± 1.5% on the 
LPS stimulated cells (Fig. 20C). In the experimental group, the percentage of CD40
+
 B1 
cells before stimulation was 55 ± 1.5% vs 74 ± 1.1% after LPS stimulation (Fig. 20C). 
As it happened with the B2 population, there was a statistically significant (p≤ 0.001) 
difference between the percentage of CD40
+
 cells from control and experimental group 
after LPS stimulation. No changes in the percentages of cells positive for MHC II were 
observed as only around 2-3% were MHC II
+


































































Figure 20: Activation status of PECs B1 and B2 populations after 24 hours in 
culture. 
Mice were treated with paraoxon or saline for three weeks. Then PECs  were 
retrieved and culture for 24 hours with or without LPS (10 g/ml). Then cells were 
stained for flow cytometry. (A) shows a representative dot plot of Positive cell 
percentages of activation markers, (B) CD40
+
 B2 cells and (C) CD40
+
 and MHC 
II
+
 B1 cells. Depicted are the mean values ±SD of 3 mice/group from a 
representative experiment. Asterisks denote statistically significant differences 































 (100%) before and after LPS stimulation (Fig. 




 cells was upregulated after LPS 







 cells was reduced from 97-98% to 72-74% after LPS stimulation in both 
groups (Fig.21A & C). No significant differences were found between control and 
paraoxon-treated groups in any of the activation markers on this myeloid population. 
Our results showed that paraoxon treatment impaired the capacity of the peritoneal B1 






























































































Figure 21: Activation status of PECs myeloid cells after 24 hours in culture. 
Mice were treated with Paraoxon or saline for three weeks. Then PECs were 
retrieved and culture for 24 hours with or without LPS (10 g/ml). Then cells 
were stained for flow cytometry. (A) shows a representative dot plot of Positive 




 and CD80+ myeloid 




 myeloid cells with or without stimulation. Depicted 
are the mean values ±SD of 3 mice/group from a representative experiment.  
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 Cytokine production by in vitro stimulated PECs 5.4.3.3
Peritoneal cells were cultured either alone or with LPS and after 24 hours supernatants 
were collected and assayed for the presence of IL-12p40 and IL-6 cytokines.  In un-
stimulated cells IL-12p40 production was below the level of detection (≤15pg/ml) in 
both groups, however, after LPS stimulation only paraoxon group had a slight but not 
statistically significant increase in the production of IL-12p40 (36 pg/ml) while in the 
control group the levels were still undetectable (Fig. 22A). In contrast, IL-6 production 
was highly induced after LPS stimulation as it went from undetectable levels (≤15pg/ml) 
to >4000pg/ml in both groups (Fig. 22B).  
Therefore, paraoxon treatment seems to have a mild effect on stimulated peritoneal 







































Figure 22: Cytokine production from PECs after 24 hours in culture. 
Mice were treated for three weeks with paraoxon or saline. Then, PECs were 
cultured with or without LPS (10 g/ml) stimulation for 24 hours. Supernatants 
were then assayed for IL-12p40 (A) and IL-6 (B) cytokines production before and 
after LPS stimulation by ELISA. Graphs depicted are the mean values ±SD of data 
from 3 independent experiments.  
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5.5 Intestinal transit 
The improved survival of paraoxon-treated mice following a lethal oral infection, could 
be attributed to enhanced intestinal motility, which implies a faster clearance of bacteria 
from the intestine, and not to the modulation of immune cells. In order to rule out this 
possibility, the effect of daily injections of paraoxon during the three weeks of treatment 
on intestinal motility was tested. 72 hours after the last injection, saline and paraoxon 
treated mice were orally inoculated with Evans blue and 15 minutes later sacrificed. 
Intestines were then aseptically removed and the distance travelled by the dye was 
measured. Fig. 23 shows no differences in the intestinal motility of paraoxon- and 
































Figure 23: Paraoxon-treatment does not increase intestinal motility 
measured 72 hours of the last paraoxon injection. 
Mice were treated with paraoxon or saline for 3 weeks then Even 
blue dye was given to each mouse by oral intubation. After 15 
minutes mice were sacrificed and intestinal transit was measured 
and calculated as percentage to the total small intestine length.  
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5.5.1 Summary of the effect of AChE inhibition on the immune cells 
 Spleen: 
 Paraoxon-treatment did not show any effect on spleen size, cellularity, 
cell phenotype and activation status or steady state cytokine gene 
expression. 
 Spleen cells of paraoxon-treated mice showed a modest increase in IL-12 
and IFN-γ production upon stimulation. 
 Purified macrophages of paraoxon-treated mice showed significant 
enhancement in their phagocytic activity. 
 MLN: 
 Paraoxon-treatment did not show any effect on size, cellularity or cell 
phenotype. 
 T cells from paraoxon-treated mice had a moderate increase in their 
activation status particularly CD8
+
 cells.  
 PECs: 
 PECs recovered from paraoxon-treated mice were significantly lower 
than saline-treated mice. 
 Upon stimulation, a mild increase in the production of IL-12 in paraoxon 
group was observed.  
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5.6 Response to systemic infection with SL1344 
5.6.1  Survival  
After three weeks of saline or paraoxon treatment, mice were infected intraperitoneally 
(i.p.) with a virulent strain of Salmonella (SL1344) at a dose of 3000 CFUs/mouse. Mice 
were, then, followed for survival (Fig. 24). The survival of paraoxon treated mice was 
slightly increased compared with saline control, as all the animals from the control 
group succumbed  by day 7 post-infection  while in the experimental group  some mice 
survived up to day 12 post-infection.  This difference, however, was not statistically 
significant and the median survival for both groups was almost identical (5 and 6 days, 
for saline and paraoxon-treated, respectively). These results indicate that AChE 
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Figure 24: Paraoxon pre-treatment did not show an effect on 
survival after systemic infection with SL1344. 
 Mice pre-treated with paraoxon or saline for 3 weeks were 
infected i.p. with SL1344 (3x10
3
). Mice were followed for 
survival up to 60 days post infection. Depicted are the mean 




5.6.2  Bacterial load in target organs 
Saline and paraoxon-treated mice were i.p. infected with SL1344 (12x10
3
 CFUs/mouse) 
then bacterial load in the different organs and compartments were determined at 
different time points. Bacteria recovered from the peritoneal cavity (Fig.25A) were ~4 ± 
2x10
3
 CFUs/ml in control group and ~14 ± 9x10
3
 CFUs/ml in paraoxon group at 2 hours 
post infection with the difference being insignificant. After 20 hours of infection 
bacteria recovered from the peritoneal cavity increased more than 40 times (~14 ± 
14x10
4
 CFUs/ml) in control group and only 2.5 times in the paraoxon group (~4 ± 
1.5x10
4
 CFUs/ml). Due to the variations within each group the differences were 
statistically insignificant. 
When bacteria recovered from peritoneal cavity was calculated as CFUs/ 1x10
6 
cell (Fig. 
25B) the result were identical to the ones showed in figure 25A.  
Bacterial load in the spleen was also analyzed and after 2 hours of infection ~10 
CFUs/mg were found in the spleen of control mice and increased 1000 times at 20 hours 
post-infection (~10
4
 CFUs/mg). Spleens from paraoxon –treated group showed almost 
identical bacterial load as control group at both time points (Fig. 25C).  
The kinetic of the bacterial load in the liver was also investigated. Similarly to the 
spleen, livers’ bacterial load were ~10
3
 CFUs/g  at 2 hours post infection, in both 
groups, that increased to ~4 ± 2x10
5
 CFUs/g in control group and ~9 ± 5.7x10
5
 CFUs/g 









































































































Figure 25: Bacterial load in peritoneal cavity and target organs following 
systemic infection with SL1344. 
Mice pre-treated with paraoxon or saline for 3 weeks were infected i.p. with 
SL1344 (12x10
3
). Mice were sacrificed at the indicated time points. 
Peritoneal fluid retrieved and bacterial load was determined as CFUs/1ml 
volume (A) and CFUs/1x10
6
 cell (B). Spleen and liver homogenates aliquots 
were plated and bacterial loads were determined. Spleen CFUs/mg (C) and 
liver CFUs/g (D) were determined. Depicted are the mean values ±SD of a 




5.6.3  Spleen and PECs cellularity 
At the same two time points after infection (2 and 20 hours), spleens were removed and 
weighted. Results showed a similar spleen weight (100-110 mg) in the animals from 
saline and paraoxon treated groups at 2 hours post-infection. After 20 hours of infection, 
the average weight of the spleen increased to 135 ± 11mg in control treated mice and 
160 ± 6mg in paraoxon treated mice (Fig. 26A). Statistical analysis revealed a 
significant (p≤ 0.01) increase in the spleen size between 2 and 20 hours only in the 
paraoxon-treated group.  
 Cell viability of spleen cells was also analyzed after infection. Viability of the spleen 
cells was slightly decreased in both groups after 20 hours of infection, probably due to 
the higher bacterial load. Figure 26B shows that at 2 hours post-infection were 53-
62x10
6 
viable cells/spleen and after 20 hours of infection these numbers were 45-
49x10
6
cells/spleen in both groups. No statistically significant differences were found 
between saline and paraoxon group. 
Cell viability was also analyzed in the cells from the peritoneal cavity.  In the control 
group, viable cells retrieved from the peritoneal cavity were around 6 ± 1x10
6
cells after 
2 hours of infection and it was a slight but significant increased after 20 hours of 
infection to 12 ± 1.1x10
6
cells (Fig. 26C). In the paraoxon treated group, the number of 































































































Figure 26: Changes in spleen and PECs after systemic infection with 
SL1344. 
Mice were treated with paraoxon or saline for three weeks and then 
infected i.p. with the virulent strain SL1344 (12x10
3 
CFUs/mouse). 
After 2 and 20 hours post infection spleen weight (A), spleen cell counts 
(B) and PECs cell counts (C) were determined. Depicted are the mean 
values ±SD of data from a representative experiment. Asterisks denote 




5.6.4 Cytokine production 
Finally, it was desired to assess whether infected animals pre-treated with paraoxon 
were able to secrete more IL-12p40 than the controls. IL-12 is an important cytokine 
that initiate the Th1 immune response needed to fight a Salmonella infection. First, IL-
12p40 was measured in the serum of infected animals and the results showed a 
significant elevation in IL-12p40 production after 2 hours of infection from ~500pg/ml 
(in both groups) to 1200 ± 400pg/ml and ~1900 ± 500pg/ml in control and paraoxon 
groups, respectively (Fig. 27A). This difference between the two groups was statistically 
not significant. After 20 hours of infection, IL-12p40 levels decreased to similar levels 
to the ones found in un-infected mice (500-600pg/ml) in both groups. 
To further assess the mouse response to infection, IL-12p40 levels were estimated in 
culture supernatants from spleen cells cultured for 24 hours. Spleen single cell 
suspension was prepared from infected saline- and paraoxon-treated animals after 2 and 
20 hours of infection. Results indicated that spleen cells from saline and paraoxon group 
increased the production of IL-12p40 after 2 hours of infection from undetectable levels 
(<15pg/ml) to 100-200pg/ml and remained on these levels after 20 hours of infection 
(Fig.27B). Despite the fact that the average amount of IL12p40 produced by spleen cells 
from paraoxon-treated animals after 2 hours of infection was higher than in the control 











































































Figure 27: Production of IL-12p40 after systemic infection. 
Mice pre-treated with paraoxon or saline for 3 weeks were infected 
i.p. with SL1344 (12x10
3
). Mice were then sacrificed at the 
indicated time points and IL-12p40 content assayed by ELISA in 
serum (A) splenocytes were obtained and cultured for 24 hours (B). 
Depicted are the mean values ±SD of data from a representative 
experiment. Asterisks denote statistically significant differences 




5.7 Response to systemic infection with BRD509E 
5.7.1  Bacterial load in peritoneal exudate cells and target organs 
Saline- and paraoxon-treated mice were infected intraperiotonealy with the attenuated 
Salmonella strain BRD509E (0.27x10
6
) then bacterial load in the different organs and 
compartments were determined at different time points. Being the site of infection, 
bacteria recovered from the peritoneal cavity (Fig. 28A) by peritoneal lavage were ~7.5 
± 5.8x10
3
 CFUs/ml in control group and ~5 ± 1.3x10
3
 CFUs in paraoxon-treated group 
after 2 days of infection. At day 7 post-infection bacteria recovered from the peritoneal 
cavity were maintained to ~7 ± 3.3x10
3
 CFUs/ml in control group while in the 
experimental group, a reduction of 38% (~3 ± 0.9x10
3
 CFUs/ml) in comparison to day 2 
was observed. No statistical differences between control and experimental groups were 
found at any time point. To confirm these results, bacteria recovered from the peritoneal 
cavity were also expressed as CFUs/ 1x10
6 
(Fig. 28B). Results confirmed no differences 
between the two groups with a discrete reduction in the bacterial load by day 7 post-
infection in paraoxon-treated group. 
Then, bacterial load in the spleen of infected animals was estimated. At day 2 post 
infection, bacterial load in the total spleen of control infected animals was ~1.8 ± 
0.4x10
5
 CFUs (Fig. 28C). In contrast, bacterial load in total spleen from paraoxon-
treated animals was ~7 ± 2.7x10
4
 CFUs, at day 2 post-infection, which was significantly 
lower than in the control group (Fig. 28D). At day 7 post-infection, bacterial load in the 
total spleen was increased in both groups, to 5 ± 1.4x10
5
 CFUs (2.8-fold increase) in 
control group and to ~2.7 ± 0.8x10
5
 (3.9 fold increase) in paraoxon-treated group. At 
101 
 
this time point the differences in the spleen bacterial load between the two groups were 
not significant.  
Finally, bacterial load in the liver was also determined. After 2 days of infection, the 
liver of control animals showed a bacterial load of ~2 ± 1x10
5
 CFUs/g which slightly 
increased to ~2.4 ± 0.9x10
5
 CFUs/g at day 7 post-infection (Fig. 28E). Similarly, liver of 
paraoxon-treated group showed, at day 2 post-infection, ~1.5 ± 0.5x10
5
 CFUs/g 
bacterial load and 1.6 ± 0.4x10
5
 CFUs/g) at day 7 post-infection. No significant 











































































































































Figure 28: Bacterial load in PECs and target organs after systemic 
infection with BRD509E. 
Mice pre-treated with paraoxon or saline for 3 weeks were infected i.p. 
with BRD509E (1.2x10
5
). Mice were sacrificed at the indicated time 
points. Peritoneal fluid retrieved and bacterial load was determined as 
CFUs/1ml volume (A) and CFUs/1x10
6
 cell (B). Spleen and liver 
homogenates were prepared, aliquots were plated and bacterial load were 
determined. Spleen total CFUs (C), spleen CFUs/mg (D) and liver 
CFUs/g (E) were determined. Depicted are the mean values ±SD of data 
pooled from 2 independent experiments. Asterisks denote statistically 





5.7.2  Spleen size 
Spleens from infected saline-treated and paraoxon-treated animals were obtained at day 
2 and 7 post-infection. Spleen weights from the two different groups were compared at 
the two different time points. At day 2 post-infection, the average weight of spleens 
from saline treated animals was 230 ± 10mg which it was significantly larger than the 
average size spleen from the paraoxon-treated group (180 ± 9mg) (Fig. 29). This smaller 
size spleen correlates with the lower bacterial burden (Fig. 28C) in the experimental 
group at day 2 post-infection.  At day 7 post-infection, splenomegaly was observed in 

































Figure 29: Splenomegaly after systemic infection with BRD509E. 
Mice pre-treated with paraoxon or saline for 3 weeks then infected 
i.p. with BRD509E (1.2x10
5
). Mice were sacrificed at the 
indicated time points and spleen weights were measured. Depicted 
are the mean values ±SD of data pooled from 3 independent 
experiments. Asterisks denote statistically significant differences 




5.7.3   Cellular phenotypic analysis 
 Peritoneal exudate cells 5.7.3.1
Next, it was needed to evaluate whether paraoxon pre-treatment can modify the 
phenotype of the macrophages present in the peritoneal cavity and, therefore, the 
response to a systemic infection. Peritoneal lavage was collected after 2 and 7 days of 
i.p. infection (with BRD509E strain) from saline- and paraoxon-treated mice. The 
percentages of various cell populations at day 2 and 7 post-infection are depicted in 
figure 30.  Fig. 30A shows no significant differences between control and experimental 
groups in the recruitment of macrophages (F4/80
+
) to the peritoneal cavity; in both 
groups, the maximum recruitment took place at day 7 post-infection, when F4/80
+
 cells 
reached about 40% of the total peritoneal cells. It was also at day 7 when these cells 
were more activated (Fig. 30B) with no differences between the saline- and paraoxon 
treated groups. The percentage of CD11b
+
 cells other than macrophages (Fig. 30C) was 
reduced ~50% at day 7 post-infection in relation to day 2, probably due to the 



















































































































Figure 30: Flow cytometric analysis of PECs after systemic infection 
with BRD509E. 
Mice were treated for three weeks with paraoxon or saline. Afterwards, 
then infected i.p. with BRD509E (1.2x10
5
). Mice were sacrificed at the 












Graphs depicted the mean values ± SD of 3 mice/group from a 




Mice, previously treated with saline or paraoxon, were intraperitonealy infected with the 
bacteria strain BRD50E9. At day 2 and 7 post infection, mice were sacrificed and flow 
cytometric analysis was performed on spleen single cell suspension. The results of this 
analysis are presented as individual graphs depicting the percentages of resting (Fig. 
31A) and activated Sca-1
+
 (Fig. 31B) T lymphocytes, and resting (Fig. 31C) and 
activated Sca-1
+
 (Fig. 31D) B lymphocytes from the total spleen pool. No significant 
differences were found between saline and paraoxon pre-treated mice in the percentage 
of total or activated lymphocytes at any time point. Graphs 30A and 30C showed that at 
day 2 post-infection, spleens contained ~25% of T cells and ~55% of B cells. At day 7 
post-infection, the percentage of both types of lymphocytes decreased (~20% of total T 
cells and ~38% of total B cells) which indicates a recruitment of cells other than 
lymphocytes to the spleen. When the activation state of these cells was analyzed, it was 
observed that the percentage of activated T cells was around 15% at day 2 and 7 post-
infection in both groups (Fig. 31B). On the other hand, the percentage of activated B 
was ~30% at both days in saline and paraoxon pre-treated mice (Fig. 31D). So, 
difference in the response to systemic bacterial infection between control and paraoxon 































Figure 31: Flow cytometric analysis of splenocytes after systemic 
infection with BRD509E. 
Mice were treated for three weeks with paraoxon or saline. Afterwards, 
then infected i.p. with BRD509E (1.2x10
5
). Mice were sacrificed at the 
indicated time points and erythrocytes-depleted splenocytes were stained 













(D) Graphs depicted the mean 






5.7.4  Cytokine production  
In order to assess the responsiveness to infection of the peritoneal exudate cells, 
peritoneal lavage from control and experimental groups was collected at day 2 and 7 
post-infection. PECs were cultured for 24 hours without further stimulation. Culture 
supernatants were collected and assessed for nitric oxide and IL-2p40 and IL-6 
cytokines. Fig. 32A shows minimum production of nitrites (< 20µM) at day 2 post 
infection in both, control and paraoxon-treated PECs, which slightly increased at day 7 
with no significant differences between the groups. When the kinetics of IL-12p40 and 
IL-6 production were analyzed (Fig. 32 B and C), the data showed that at day 2 post-
infection, PECs from both groups produced ~800pg/ml of IL-12p40 and ~1500pg/ml of 
IL-6. These levels were reduced after 7 days of infection (~200pg/ml IL-12p40 and 
~1000pg/ml IL-6) in both groups probably due to the migration of the bacteria to 
systemic organs. Differences between paraoxon and control group showed to be not 
























Furthermore, the functional ability of the spleen cells was assessed by the production of 
nitric oxide and IL12p40, IL-6 and IFN-γ cytokines. Spleen single cell suspensions were 
prepared from infected animals pre-treated with saline or paraoxon. Cells were cultured 





















































Figure 32: Functional response of PECs after systemic infection with 
BRD509E. 
Infected mice previously treated with paraoxon or saline for 3 weeks 
were sacrificed at the indicated time points. PECs were retrieved and 
cultured. 48 hours supernatants were assayed for nitrite content by the 
Griess method (A). 24 hours supernatants were assayed for IL-12 (B) 
and IL-6 (C) by ELISA. Depicted are the mean values ±SD of data 




production by spleen cells (Fig. 33A) was <10µM in both groups and by day 7 after 
infection the production increased to ~30µM in both groups. When the production of IL-
12p40 pro-inflammatory cytokine was investigated (Fig. 33B), spleens from control and 
experimental animals exhibited a 4-fold increase from day 2 to day 7, from 200 to 800-
900pg/ml. The increase in the production of IL-6 (Fig. 33C) was shown to be around 10 
folds (from 40 to 300-400pg/ml) higher at day 7 than at day 2 post-infection in both, 
saline and paraoxon-treated groups. Finally, the production of IFN-γ, an essential T cell 
cytokine in the immune response to Salmonella was measured. As it has been described 
for IL-12p40 and IL-6, spleen cells from both groups produced more IFN-γ after 7 days 
of infection than at day 2 post-infection (Fig. 33D). Spleens from saline-treated mice 
produced 92 ± 62pg/ml of IFN-γ at day 2 post-infection and 140 ± 70pg/ml after 7 days 
of the infection. Spleens from paraoxon-treated group at day 2 post-infection produced 
30 ± 0.1pg/ml of IFN-γ and around 500 ± 200pg/ml at day 7 post-infection which 
represent 16 fold increase in the production of this cytokine in paraoxon-treated group. 
Due to the high variability among the individuals within each group, the differences 
between the groups were not significant at any time point. 
In general, spleen cells produced more cytokines and nitrates after 7 days of systemic 























Figure 33: Functional response of spleen cells after systemic infection with 
BRD509E. 
Infected mice previously treated with paraoxon or saline for 3 weeks were 
sacrificed at the indicated time points. Spleens were collected. Spleen 
single cell suspensions were cultured. 48 hours supernatants were assayed 
for nitrite content by the Griess method (A).24 hours supernatants were 
assayed for IL-12 (B), IL-6 (C) and IFN-γ (D) by ELISA. Depicted are the 






































































5.7.5  Kinetics of fecal IgA and bacterial load  
Fecal immunoglobulin A (IgA) was measured after intraperitoneal infection with 
BRD509E (1.4x10
5
), an attenuated strain of Salmonella, at different time points by 
ELISA. Fecal Salmonella specific IgA was followed weekly for 91 days after the 
infection. Figure 34A shows that IgA was progressively increasing in the feces during 
the first 37 days after infection, when IgA levels reached the maximum and maintained 
constant until day 79 when they started declining. It can be observed in Fig. 34A that, 
although both groups exhibited similar pattern in the production of IgA, during the first 
35 days the levels of IgA produced by infected paraoxon-treated animals is higher than 
in the infected saline group.  However, no significant differences were detected between 
the two groups. 
Fecal CFUs were also determined weekly during the first month after the systemic 
infection. Fecal CFUs were detected in only some of the animals at all time points and 







Figure 34: Kinetics of fecal IgA and bacterial load following systemic 
infection with BRD509E. 
Mice were treated with paraoxon or saline for 3 weeks then infected i.p. with 
BRD509E bacterial strain (1.4x10
5
). Feces were collected at the indicated 
time points for determining fecal IgA levels (A) and fecal bacterial load (B).  













































5.8 Summary of effect of paraoxon on the immune response to systemic 
infection 
 Systemic infection with SL1344 (virulent strian): 
 Paraoxon treatment did not show any effect on mice survival or bacterial 
load in the different sites. 
 IL-12 production was moderately higher in paraoxon group at 2 hours 
post-infection in both serum and spleen cells. 
 Systemic infection with BRD509E (attenuated strain): 
  Paraoxon-treated mice had a significantly lower bacterial load in the 
spleen at day 2 post-infection accompanied by smaller spleen size in 
comparison to saline-treated mice. 
 At day 7 post-infection both groups showed similar bacterial load in the 
different sites. 
 No differences were observed in cytokines and nitric oxide production or 
cell phenotype and activation status in splenocytes and PECs in both 








5.9 Response to an oral infection with SL1344 
5.9.1 Bacterial load in the different organs 
Mice were treated with saline or paraoxon for three weeks, and then infected by oral 
inoculation with the virulent Salmonella strain SL1344. Mice were sacrificed at day 2, 4 
and 7 post-infection, and spleen, liver and MLN aseptically removed. Bacterial load was 
estimated in the different organs and fecal pellets.  
At day 2 post-infection, bacterial load in the spleen, liver and MLN were undetectable. 
However, bacterial shedding was detected in the fecal pellets of some mice which were 
0.2 CFUs/mg in the control group and 0.1 CFUs/mg in paraoxon-treated group. (Fig. 
35A)  
At day 4 post-infection, bacterial load in only two mice, one from each group, was 
detected in the spleen, liver, and fecal pellets and were less than 60 CFUs/mg (Fig. 
35B). Bacteria were not detectable in the Peyer’s patches (PP) or MLN of any mouse. 
Up to this point paraoxon pre-treated mice did not show any significant differences in 
comparison to control group. 
However, massive expansion in the bacterial growth was observed 7 days after infection 
(Fig. 35C). Control group presented a bacterial burden of 25x10
3 









CFUs/mg in the MLN and around 100 CFUs/mg in 
fecal pellets. On the other hand, paraoxon-treated mice showed a significantly lower 
bacterial burden in spleen (300 CFUs/mg 83 folds less), liver (30 CFUs/mg 16 folds 
less), MLN (1CFUs/mg 3000 fold less) and feces (less than 1 CFU/mg 3 fold less) than 
control mice. All the mice in the control group showed bacteria in their organs; 
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however, only 66% mice from the paraoxon-treated group contained bacteria in their 
organs.  
In figure 35D summarizes the kinetic of bacterial dissemination to the different organs, 















Figure 35: Reduction in the bacterial load in target organs of paraoxon pre-
treated mice after 7 days of oral infection. 
Mice were treated with saline or paraoxon for 3 weeks and, then, infected 
orally with SL1344 (10
4
). Mice were sacrificed and organs homogenates 
aliquots were plated to determine bacterial load. Bacterial loads were 
determined as CFUs/mg in spleen, liver, MLN and feces at day 2 (A), 4 (B) 
and 7 (C) post infection. (D) Shows the change in bacterial load in the 
different organs over the course of infection. Graphs depicted the mean values 
±SD of data from 2-3 independent experiments. Asterisks denote statistically 
significant differences between control and experimental groups * p<0.05, 
**p<0.01, ***p<0.001. Statistical analysis was done using Mann-Whitney 
test. UD: un-detectable. 
  







































































5.9.2  Spleen and mesenteric lymph nodes size 
Spleen and MLN from infected saline- and paraoxon-treated mice were obtained and 
weighted at day 2, 4 and 7 post-infection.  After 2 days of infection, spleens from both 
groups presented a normal weigh. By day 4 post-infection a non-significant increase in 
the size of paraoxon-treated animals was observed. It was at day 7 post-infection when 
spleens from saline-treated animals showed a 2 fold increase while paraoxon-treated 
mice showed only 1.3 fold increase. The weigh difference between the two groups was 
statistically significant (p<0.01) (Fig. 36A). The splenomegaly observed at day 7 in the 
saline group correlates with the high bacterial load found in these mice. 
When the MLN weigh was analyzed at the three time points, in the control and 
experimental group, no differences were found between the two groups. Moreover, 
MLN size remained unchanged at all times points regardless of the bacterial load in the 
















































Figure 36: Changes in spleen and MLN following oral infection. 
Mice were treated with Paraoxon or saline for three weeks. Mice were then 
infected orally with a dose of 1x10
4
 CFUs/mouse of SL1344. Then at day 2, 
4 and 7 post infection spleen weights (A) and MLN (B) were determined. 
Depicted are the mean values ±SD of data pooled from 2-3 independent 
experiments at each time point. Asterisks denote statistically significant 
differences between control and experimental groups **p<0.01.  
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5.9.3  Spleen and MLN cells population and activation status 
Single cell suspensions of spleen and MLN were prepared from orally infected mice, 
pre-treated with saline or paraoxon, and sacrificed at day 7 post-infection. The different 
cell populations were analyzed in both organs by flow cytometry. Splenocytes from non-
infected mice were used as control. As shown in figure 37, uninfected spleens were 
constituted by 38 ± 1% CD3
+ 
T cells, 41 ± 5% CD19
+
 B cells and 15 ± 2% CD11b
+
 
cells, additionally spleens contained other cells like NK and dendritic cells in much 
lower percentage. The majority of those cells were negative for the activation marker 
Sca1.  When the spleen cell populations, from saline pre-treated mice, were analyzed a 




 cells (17 ± 6% and 43 ± 4.3%, 
respectively) compared to the unstimulated group, and dramatic increase in the 
percentage of CD11b
+
 cells (35 ± 2.6%) was shown (Fig. 37). Moreover, the three cell 
populations had an increase in the expression of Sca1, as 71% of CD3
+ 
cells, 98% of 
CD19
+





Interestingly, the analysis of the splenic cell population in infected paraoxon-treated 
mice (Fig. 36) showed no significant changes, compared to the non-infected mice, in the 
percentages of the different populations ( 40 ± 2.5% CD3
+
, 49 ± 4% CD19
+
 and 8 ± 1% 
CD11b) or in the expression of Sca1 as 15% of CD3
+
 cells, 2% of CD19
+
 cells and 1% 
of CD11b
+





The graphs in figure 37 depicted the average percentages of the different spleen cell 
populations (Fig. 38A) as well as their Sca1 expression (Fig. 38B). Additionally, the 
same results were expressed as number of cells/mg of spleen (Fig. 38C-D) which 
confirmed that the level of infection in spleens from paraoxon-treated group was very 





















Figure 37: Flow cytometric analysis of spleen population and the activation 
status. 
Mice were treated for three weeks with paraoxon or saline. Mice were then 
infected orally with a dose of 1x10
4
 CFUs/mouse of SL1344. At day 7 post 
infection erythrocytes-depleted splenocytes were stained for flow cytometry. 
Representative dot plots show positive cell percentage of CD3, CD19, 














Then, the characteristics of each population were analyzed in detail. First, the two 
subpopulations of T cells were studied. Un-infected mice and infected paraoxon-treated 
mice showed similar percentages of CD4
+
 (26 ± 1% vs 30 ± 0.5%) and CD8
+
 (12% in 
both groups) cells (Fig. 39), out of the total cell population, with also similar expression 











 cells <1% were CD69
+
 and <6% were CD25
+
. However, in infected saline-pre-
treated mice, the percentage of CD4 and CD8 populations were much lower, 10 ± 5.5% 













































































Figure 38: Spleen cell population and their activation markers at day 7 post-
infection. 
Mice were treated with saline or paraoxon for 3 weeks and, then, orally 
infected with SL1344 (10
4
). 7 days after infection, mice were sacrificed, spleen 
was collected and single cell suspension was stained for flow cytometry.  
Graphs depict the spleen total cell population percentages (A), spleen cells 
activation markers percentages (B), total population cell numbers (C) and 
activation markers cell numbers (D). Graphs depicted the mean values ±SD of 
data from a representative experiment. Asterisks denote statistically significant 
differences between groups * p<0.05, **p<0.01.  
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number of T cells previously described. On CD4
+
 cells the percentage of cells 
expressing CD69 was 19% (2 folds higher than in the other two groups), but no 




 cells were found. The percentage of CD8
+
 
cells expressing CD69 and CD25 were similar to the un-infected and infected paraoxon-
treated groups (Fig. 38). In figure 40 A-C, average of the percentages of these two 




























Figure 39: Flow cytometric analysis of spleen T cells and their activation markers at 
day 7 post-infection. 
Mice were treated for three weeks with paraoxon or saline. Mice were then infected 
orally with a dose of 1x10
4
 CFUs/mouse of SL1344. At day 7 post infection 
erythrocytes-depleted splenocytes were stained for flow cytometry. Representative 
dot plots show positive cell percentage of CD3/CD4, CD3/CD8 and their activation 




















 (macrophages) population was further analyzed for the expression of 




 cells was 
around 4% in the un-infected and infected paraoxon-treated groups, all of them were 
negative for the expression of CD40, around 40% were CD86
+
 and around 15% were 
MHCII
+




 cells were around 9% (Fig. 
41) of the total spleen population. Moreover, 35% of them expressed CD40, 74% 
Figure 40: T cells subpopulations and their activation markers in 
spleen at day 7 post-infection. 
 Mice were treated with saline or paraoxon for 3 weeks and, then, 
orally infected with SL1344 (10
4
). 7 days after infection, mice 
were sacrificed, spleen was collected and single cell suspension 
was stained for flow cytometry. Graphs depict T cells sub-
population percentages (A), CD8 activation markers percentages 
(B) and CD4 activation markers percentages (C). Graphs depicted 








































































expressed CD86 and 46% were MHC II
+
 indicating that CD11b cells were highly 





























Figure 41: Flow cytometric analysis of splenic myeloid cells and their activation 
markers at day 7 post-infection. 
Mice were treated for three weeks with paraoxon or saline. Mice were then 
infected orally with a dose of 1x10
4
 CFUs/mouse of SL1344. At day 7 post 
infection erythrocytes-depleted splenocytes were stained for flow cytometry. 
Representative dot plots show positive cell percentage of CD11b/F4/80 and their 











Next, the cell populations in the MLNs were analyzed. Figure 43 depicted the dot plots 
of one representative mouse in each group (un-infected, infected saline-treated and 
infected paraoxon-treated). The percentages of the three main cell populations in un-
infected MLN were 74% CD3
+
 T cells, 33% CD11b
+
 B cells and 2% CD11b
+
 cells. 
MLNs from infected mice (saline-and paraoxon-treated) presented similar percentages 
in those cell populations (Fig. 43). However, when Sca1 expression was analyzed, the 
majority of the cells in MLNs from infected saline-treated mice were activated as 70% 
of CD3
+
, 95% of CD19
+




 unlike the cells in the un-
infected and paraoxon-treated mice (Fig. 43). The cell percentages calculated from the 
flow cytometry are represented in Fig. 43A-B and they were in agreement with the result 





































Figure 42: Myeloid cell population in the spleen at day 7 post-infection. 
Mice were treated with saline or paraoxon for 3 weeks and, then, orally 
infected with SL1344 (10
4
). 7 days after infection, mice were sacrificed, 
spleen was collected and single cell suspension was stained for flow 
cytometry. Graphs depict myeloid cells percentages (A) and their 
activation markers CD40 and MHC II (B). Graphs depicted the mean 












Figure 43: Phenotypic analysis and activation markers of total MLN population at 
day 7 post-infection. 
Mice were treated for three weeks with paraoxon or saline. Mice were then 
infected orally with a dose of 1x10
4
 CFUs/mouse of SL1344. At day 7 post 
infection MLN cells were stained for flow cytometry. Representative dot plots 
show positive cell percentage of CD3, CD19, CD11b, CD3/Sca-1, CD19/Sca-1 




































 cells or their activation status, represented by the 
expression of CD69 and CD25. Figure 46(A-C) depicted the average cell percentages in 


















































































Figure 44: MLN population and their activation markers at day 7 post-
infection. 
Mice were treated with saline or paraoxon for 3 weeks and, then, orally 
infected with SL1344 (10
4
). 7 days after infection, mice were sacrificed, spleen 
was collected and single cell suspension was stained for flow cytometry.  
Graphs depict MLN total cell population percentages (A), activation markers 
percentages (B), total population cell numbers (C) and activation markers cell 
numbers (D). Graphs depicted the mean values ±SD of data from a 


































Figure 45: Flow cytometric analysis of splenic T cells and their activation 
markers at day 7 post-infection. 
Mice were treated for three weeks with paraoxon or saline. Mice were then 
infected orally with a dose of 1x10
4
 CFUs/mouse of SL1344. At day 7 post 
infection MLN cells were stained for flow cytometry. Representative dot plots 
show positive cell percentage of CD3/CD4, CD3/CD8 and their activation 




















Figure 46: MLN T cell population and their activation markers at 
day 7 post-infection. 
Mice were treated with saline or paraoxon for 3 weeks and, then, 
orally infected with SL1344 (10
4
). 7 days after infection, mice 
were sacrificed, spleen was collected and single cell suspension 
was stained for flow cytometry. Graphs depict T cells sub-
population percentages (A), CD8 activation markers percentages 
(B) and CD4 activation markers percentages (C). Graphs depicted 





































































5.9.4  Cytokine production 
Next, the levels of IL-12 pro-inflammatory cytokine in the serum of un-infected and 
infected animals, pre-treated with saline or paraoxon, at day 2, 4 and 7 post- infection 
were investigated (Fig.47A).  IL-12p40 concentration in the serum of un-infected mice 
was ~500 pg/ml. After 2 and 4 days of infection IL-12p40 concentration increased to 
~800 pg/ml (1.6 fold increase), in both; saline and paraoxon-treated groups. At day 7 
post-infection, the levels of IL-12p40 increased to were ~1500 pg/ml (3 folds increase) 
in the saline-treated group, but not in the paraoxon-treated mice where the levels 
remained below 1000 pg/ml. 
The capacity of splenocytes to produce cytokines (IL-12p40, IL-6, IL-10 and IFN-γ) 
was also investigated. At day 7 post-infection, splenocytes from infected mice, pre-
treated with either saline or paraoxon, were cultured without any stimulation. After 24 
hours, supernatants were collected and assayed for the different cytokines. Results 
showed (Fig. 47B-C) in general, a lower production of cytokines in the paraoxon-treated 
mice than in the saline-treated group although no significant differences were observed 
on the IL12p40 (76 ± 30pg/ml vs 159 ± 80pg/ml), IL-6 (20 ± 3pg/ml vs 88 ± 50pg/ml) 
and IL-10 (162 ± 120pg/ml vs 310 ± 125pg/ml) production. However, the production of 
IFN-γ by splenocytes from the saline-treated group was significantly higher (6.6 folds) 














Figure 47: Cytokines produced in serum and by splenocytes of 
Salmonella infected mice. 
Mice were treated with saline or paraoxon for 3 weeks and, then, 
infected orally with SL1344 (10
4
). Serum IL-12p40 was measured 
at indicated time points (A). 7 days after infection, mice were 
sacrificed and single spleen cell suspensions cultured. Culture 
supernatants were collected and tested for IL-12p40 and IL-6 (B) 
and IL-10 and IFN-γ (C). Graphs depicted the mean values ±SD of 
data from 2 independent experiments. Asterisks denote statistically 
significant differences between control and experimental groups * 
p<0.05. 
  




















































5.9.5  IgA estimation in fecal pellets and determination of bacterial load 
Fecal pellets were collected at the end of the three weeks treatment with saline or 
paraoxon before oral inoculation with virulent SL1344 and at different days after 
inoculation. Total fecal IgA content was estimated before infection and at day 4 and 7 
post-infection. In figure 48A it is shown that the levels of total un-specific IgA did not 
change during the infection in any of the two groups for which we can conclude that 
paraoxon-treatment did not enhance the production of total IgA at any time point.  
Additionally, specific anti-Salmonella IgA antibody was estimated after 4 and 7 days of 
oral infection (Fig.48B). The results showed un-detectable levels of anti-Salmonella IgA 
at day 4 post-infection in saline- as well as in paraoxon-treated mice. By day 7 post-
infection, anti-Salmonella IgA antibody were detectable in both groups. Paraoxon group 
showed higher levels than the saline but the differences were, again, not significant.  
Next, the effect of the inhibition of the AChE on the clearance of live bacteria at the 
level of the intestine, before it disseminates to the systemic organs which, could 
somehow protect the mice from a lethal infection was elucidated. After infection by oral 
inoculation of SL1344, feces were collected at different time points up to day 10 post-
infection.  
 Early during the infection, at days 2 and 4 fecal, CFUs were very low (lower than 0.1 
CFUs/mg) in both groups with no significant differences between them. At day 7 post-
infection control group showed a massive increase in the fecal CFUs reaching 100 
CFUs/mg, by day 10 post-infection CFUs were increased by 10 folds reaching around 
900 CFUs/m (Fig. 48C). However, at day 7 post-infection, mice from the paraoxon 
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group showed 50 times less fecal load (around 2 CFUs/mg) than the saline group, a 
difference that was statistically significant.  At day 10 post-infection, paraoxon-treated 
mice increased their bacterial shedding to 67 CFUs/mg which represent 10 folds less 





















































































Figure 48: Kinetic of fecal bacterial load and IgA following an oral 
infection with SL1344. 
Mice were treated with paraoxon or saline for 3 weeks then infected 
orally with SL1344 (1x10
4
). Feces were collected at the indicated time 
points for determining total fecal IgA levels (A), anti-Salmonella fecal 
IgA levels (B) and fecal bacterial load (C). Depicted are the mean values 
±SD of data pooled from 2-3 independent experiments at each time 
point. Asterisks denote statistically significant differences between 




Results indicated that paraoxon treatment did not induce an increase in the bacterial 
shedding, on the contrary, feces from paraoxon-treated mice contained less bacterial 
load than the ones from the control group. Therefore, the lower systemic bacterial load 
could not be explained by a faster clearance of the bacteria.  
5.9.6  In-vivo bioluminescent imaging 
After oral inoculation of the mice with a bioluminescent strain of Salmonella 
(SL1344::lux), bacterial dissemination was followed by live imaging.  In order to 
facilitate the visualization of the bacteria, mice were inoculated, after three weeks of 
treatment with saline or paraoxon, with high dose of SL1344::lux (1x10
5
 CFUs/mouse). 
Mice were then imaged at different time points until they succumbed to the infection, 
usually between day 0 and day 16 post-infection (Fig.49). 
Initially, all the mice in both groups showed a localized distribution of the bacteria in the 
intestinal region. At day 7 post-infection some of the animals from the control group 
showed a rapid and massive dissemination of the bacteria to the systemic organs and all 
of them succumbed to the infection by day 9 after infection. On the contrary, paraoxon-
treated mice showed a delayed dissemination of the bacteria to the systemic organs that 
started being apparent at day 8 (not shown). Moreover, some of the mice survived up to 
day 16 after infection.    
These data suggested that a delay on the bacterial translocation at the level of the 
intestinal epithelium could be the key for the enhanced survival of infected mice pre-






















Figure 49: In-vivo bioluminescent imaging of Salmonella 
infected mice. 
Following 3 weeks exposure to saline or paraoxon, mice were 
infected orally with 10
5
 SL1344::lux. Control (A) and paraoxon 
pre-treated (B) mice were imaged ventrally starting at 3h 
postinfection (D.0). Data are representative of 2 independent 
experiments (5 mice/group). Color scale ranges from 1,450 
photons/sec/cm
3













5.10 Summary of the effect of AChE inhibition on the immune response 
following oral infection  
 At early time points following oral infection no differences were observed 
between paraoxon- and saline-treated mice in the bacterial load and serum IL-12. 
 At day 7 post infection with SL1344: 
 Significantly lower bacterial load in MLN, spleen and liver in paraoxon-
treated mice 
 Lower state of activation of splenocytes and MLN cells in paraoxon-
treated mice 
 Lower production of inflammatory cytokines in paraoxon-treated mice 










5.11 Anti-microbial peptides in the intestinal epithelium 
Next, it was decided to investigate whether paraoxon treatment has any effect on the 
intestinal mucosa as it is the first barrier that bacteria will encounter following an oral 
infection. Therefore, the expression of the anti-microbial peptides (AMPs) produced by 
Paneth cells in the small intestine was studied. The last part of the small intestine 
(ileum) was aseptically removed from mice treated for three weeks with either saline or 
paraoxon. Small intestine was also obtained from mice treated with saline or paraoxon 
and then infected (by oral inoculation) with SL1344 Salmonella strain (10
4
 
CFUs/mouse), at day 4 post-infection.  
The results showed that relative mRNA expression of AMPs like defensin 1, defensin 4, 
CRS1C, CRS4C, Ang-4 and the enzyme MMP-7 were almost identical in the intestinal 
cells from control and paraoxon-treated mice (Fig.50A-C), meaning that paraoxon 
treatment did not induce an up-regulation of this peptides. However, the expression of 
RegIII-γ was 3-folds higher in paraoxon-treated mice than in control animals, even 
though, the relative expression of this gene showed to be not significant (Fig.50C). 
Figure 50D shows the fold increase in the expression of AMPs in the paraoxon-treated 




















The expression of these genes was also analyzed in intestinal epithelial cells of infected 
mice after 4 days of infection. In control mice, the expression of defensin 1, defensin 4, 
MMP-7, RegIII-γ and Ang-4 were up-regulated by 6-folds, 2-folds, 3-folds, 3-folds and 
6-folds respectively, but no major changes were observed in CRS1C and CRS4C 
expression after 4 days of oral infection in comparison to saline un-infected mice 





































































































































C B A 
Figure 50: Gene expression of anti-microbial peptides (AMPs) in epithelial cells of 
un-infected mice. 
Mice were treated with paraoxon or saline for 3 weeks. Mice were sacrificed and 
intestinal epithelial cells were isolated. RNA was extracted from the isolated 
epithelial cells, converted to cDNA and ran for real-time PCR. Graphs depicted the 
mRNA relative expression each gene in both control and paraoxon groups (A-C) 
and fold change in the expression of AMPs of paraoxon in comparison to control 
(D). Depicted are the mean values ±SD of data pooled from 2 independent 
experiments for fold change and a representative experiment for mRNA relative 




peptides, before and after infection. Interestingly, paraoxon pre-treated mice showed 
same pattern but with lower levels of induction as the expression of defensin 1, MMP-7, 
and Ang-4 as they were up-regulated by 3-folds, 1.5-folds, and 3-folds, respectively. 
However, no changes were observed in defensin-4, CRS1C, CRS4C and RegIII-γ 
expression after 4 days of oral infection in comparison to paraoxon un-infected mice 
(Fig.52A). In figures 52B-C were represented the relative expression of each of these 





































































































































D C B 
Figure 51: Gene expression of AMPs in small intestine epithelial cells of infected 
saline-treated mice. 
Mice were treated with paraoxon or saline for 3 weeks. Intestinal epithelial cells 
were isolated from control un-infected mice and after 4 days of oral infection. RNA 
was extracted from the isolated epithelial cells, converted to cDNA and ran for real-
time PCR. Graphs depicted fold change in the expression of AMPs of control 
infected in comparison to control un-infected (A) and the mRNA relative expression 
each gene in both control infected and un-infected groups (B-D). Depicted are the 
mean values ±SD of data pooled from 2 independent experiments for fold change 
and a representative experiment for mRNA relative expression graphs. Asterisks 



























































































































































D C B 
Figure 52: Gene expression of AMPs in small intestine epithelial cells of 
infected paraoxon-treated mice. 
Mice were treated with paraoxon or saline for 3 weeks. Intestinal epithelial 
cells were isolated from paraoxon un-infected mice and after 4 days of 
oral infection. RNA was extracted from the isolated epithelial cells, 
converted to cDNA and ran for real-time PCR. Graphs depicted fold 
change in the expression of AMPs of paraoxon infected in comparison to 
paraoxon un-infected (A) and the mRNA relative expression each gene in 
both paraoxon infected and un-infected groups (B-D). Depicted are the 
mean values ±SD of data pooled from 2 independent experiments for fold 
change and a representative experiment for mRNA relative expression 




5.12 Morphological analysis of the intestinal mucosa 
Finally, it was investigated whether paraoxon treatment induces any morphological 
changes at the level of the intestinal mucosa that could affect the translocation of 
bacteria from the intestinal lumen to the submucosa. Small intestine (ileum) was 
collected, from saline and paraoxon-treated mice, and prepared for microscopic 
observation. 
5.12.1 Light microscopy 
Light microscopy examination of the small intestine (ileum) revealed the intestinal 
mucosa with villi and crypts. Villi were covered by columnar absorbing cells and goblet 
cells. At the end of the crypts of Lieberkuhn, groups of Paneth cells were observed with 
their cytoplasm filled of abundant cytoplasmic granules. In figures 53A-B are shown 
two intestinal sections from two different saline-treated mice. 
Tissue sections from paraoxon-treated mice revealed the same structure, with no 
obvious morphological changes. However, in some areas we could observe less number 
of granules in the cytoplasm of Paneth cells located in the crypts (Fig. 53C). Sometimes, 
some of these granules looked to be outside the cells. Moreover, the goblet cells seemed 




































Figure 53: Ileum sections stained with Hematoxilin and Eosin. 
Ileum sections stained with Hematoxilin and Eosin from saline (A-B) or 
paraoxon (C-D)-treated mice. Goblet cells (black arrows) can be seen 
between the columnar absorbing cells. Paneth cells (white arrows) at the 
bottom of the intestinal crypts contain a cytoplasm full of acidophylic 
granules.  Areas with degraulated goblet cells and Paneth cells are seen in 
sections from the experimental group. Images were taken at x 400 





5.12.2 Electron microscopy 
Mice treated for three weeks with saline or paraoxon were sacrificed and their small 
intestine aseptically removed. The terminal part of the small intestine (Ileum) was 
processed for electron microscopy. Ultrastructural examination of the saline-treated 
mice intestinal epithelium showed the presence of columnar absorbing cells with apical 
microvilli and goblet cells. Goblet cells presented an apical part distended with large 
rounded mucous globules (Fig. 54A and B). However, in the paraoxon-treated group, 
intestinal goblet cells appeared almost depleted of the mucous globules that were 
released to the lumen of the intestine (Fig. 54C and D). This release appeared to be 
massive, leading to the disruption of the apical cytoplasmic membrane, the release of 





























Figure 54: Transmission electron micrographs of smal intestine (ileum) 
epithelium showing goblet cells. 
Goblet cells in ileum sections from saline treated mice (A-B) and 
paraoxon treated animals (C-D).  Goblet cells (arrow)in saline treated 
animals presented a distended apical part that contains large rounded 
mucous globules of moderate electron density. In contrast, goblet cells 
from paraoxon treated animals showed either an active degranulation 
(C) of their granules to the intestinal lumen (L) or complete 







Paneth cells, in the intestine of the saline group, were seen in groups at the bottom of the 
crypts of Lieberhuen, These cells were filled with large spherical electron dense 
granules (Fig. 55A) that in some cases were surrounded with clear halos (Fig. 55B). The 
basal part of these Paneth cells contained abundant layered endoplasmic reticulum, 
mitochondria and a nucleus with a prominent nucleolus (Fig. 55C). In the paraoxon 
group, Paneth cells were found less abundant and to have fewer electron dense granules 
of various sizes (Fig. 56A) compare to the saline group. Enteroendocrine cells were 
often seen in close proximity to Paneth cells (Fig. 56A). Additionally, numerous cells 
with enlarged endoplasmic reticulum and small granules were seen (Fig 56B). 
Moreover, cells with dilated endoplasmic reticulum and with no granules were observed 
(Fig 56B), these cells could be Paneth cells that had lost the electron dense secretory 
granules and the endoplasmic reticulum which was replaced by cytoplasmic vesicles. 
Additionally, mitotic figures were observed in the close vicinity of the Paneth cells (Fig. 
56C) which could indicate the arrival of new cells that will differentiate into new Paneth 



























Figure 55: Transmission electron micrographs of smal intestine (ileum) 
epithelium showing goblet cells. 
Electron micrograph of Paneth cells in the crypt base of  the small 
intestine of saline treated mice .  A. Their cytoplasm is filled with large 
spherical granules (white arrows) B. some of them surrounded by clear 
halos (red arrows). C. Higher magnification shows a Paneth cell with 
abundant endoplasmic reticulum (ER) in the proximity of the nucleus and 













Figure 56: Transmission electron micrograph of the ileum epithelium of 
paraoxon-treated mice. 
(A) Paneth cell (PC) containing electron dense spherical granules of 
different sizes (white arrows), next to a enteroendocrine cell (E) 
containing small electron dense granules.  (B) group of cells in the 
intestinal cripts with enlarged endoplasmic reticulum (ER) and lack of 
granules. (C)  Mitotic cells (M) can be observed approaching the intestinal 
epithelium. (L) Intestinal lumen, (N) nucleus, (GC) goblet cell. 






Chapter 6 : Discussion  
Previous studies in our laboratory have shown that inhibition of AChE acts on the 
immune system in an immune-regulatory fashion, and confers protection against lethal 
Gram-negative bacterial infection (43). The aim of this study is to elucidate the 
mechanism by which AChE inhibition and, therefore, an increase in the levels of ACh, 
enhanced the survival of infected mice.  
In all our experiments, the effectiveness of the paraoxon was monitored by measuring 
the activity of AChE in blood during the administration period. In every experiment, the 
AChE activity was inhibited by 45-50% which correlated with a slower growth of the 
mice as we have previously reported (43,98).  
First we investigated the effect that subchronic administration of paraoxon could have 
on the main lymphoid organs involved in the immune response and that could influence 
the body response to a bacterial infection. So, we started by analyzing the spleen, as an 
essential secondary lymphoid organ, and the mesenteric lymphoid node (MLN) 
important for the immune response to gastro-intestinal infections. Additionally, PECs 
were also investigated as the daily administration of paraoxon took place through the 
intraperitoneal route. 
Our data showed no major influence of AChE inhibition pre-treatment on the spleen 
weights or viable cell counts although weights and counts tended to be lower in 
paraoxon pre-treated mice. This observation was more significant in the PECs cell 
counts as they were significantly reduced by one third in paraoxon pre-treated mice. 
These observations were accompanied with no change neither in spleen nor PECs 
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phenotypic analysis. In-vitro studies on murine EL4 T cell line had shown that 
paraoxon, induced toxic effects characterized by disruption of the mitochondria 
transmembrane potential, release of cytochrome C and activation of caspases (93,94).  
Therefore, the reduction in viable cell counts in PECs, and to lesser extend in spleen, 
could be a result of the induced apoptosis by paraoxon. The fact that cells phenotype 
was not affected in paraoxon pre-treated mice could indicate that the apoptosis is not 
selective and does not target any specific cell type.  
In addition, AChE inhibition did not affect the spleen cells phenotype or their activation 
status which correlated with no changes on pro-inflammatory cytokines production, at 
protein levels as well as gene expression, from un-stimulated spleen cells. Moreover, 
splenic macrophages and T cells from paraoxon-treated animals did not showed any 
delay or inhibition on the production of pro-inflammatory cytokines after in vitro 
stimulation. However, we observed a moderate but not significant increase in the 
production of IL-12 after LPS stimulation and IFN-γ in ConA stimulated cells.  Several 
studies had addressed the effect of AChE inhibitors on the immune system using 
different inflammatory models and different treatments, and not always with the same 
outcome which makes difficult to extract a definitive conclusion. Our results were in 
agreement with a study in which the AChE inhibitor pyridostigmine bromide, 
administered for 28 days, reported no effect on the humoral immune response but it had 
a moderate effect on splenic T cells response to ConA stimulation, experimenting a 
moderate increase in the production of IL-2 and IFN-γ (91). In another study,  the i.p. 
administration (3 times a week for five weeks) of the AChE inhibitor dimethoate 
showed no effect on the normal response of immune cells of the brain toward LPS 
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stimulation, although the compound on its own resulted in an increase of TNF-α and IL-
6 mRNA expression (92).  
As mentioned earlier, in our model, AChE inhibition did not have an inhibitory effect on 
the immune response to mitogens. However, we found that it does have an effect on the 
CD11b
+
 splenic cells showed by a significant enhancement in their phagocytic activity. 
Similar finding was demonstrated  in a study on peritoneal and intestinal macrophages 
which showed an increase in their phagocytic activity after being stimulated with 
nicotine and ACh in-vitro (117).     
 Furthermore, our results showed that paraoxon pre-treatment did not have any effect on 
the MLNs weights, cell viability or cells phenotype. However, we found an increase in 
the number of Sca-1
+
 among the CD8 cells as well as an increase in the expression of 
CD25 following AChE inhibition treatment. It is known that IL-2 receptor (CD25) 
respond in a autocrine pattern to IL-2 produced by activated T cells and induce cell 
proliferation (118) and that Sca-1 (Ly-6A/E) expression is up-regulated in response to 
IFN-γ and TNF (119). Therefore, both markers are involved in the activation of T cells, 
thus our data suggests that AChE inhibition resulted in an increase in the activation 
status of MLN T cells. 
Phenotypic analysis of the peritoneal cavity cells revealed no changes after treatment 
with AChE inhibitor. However, following in vitro LPS stimulation, B1 and B2 cell 
populations showed to have a partially impaired induction of CD40 expression. In B 
cells, CD40 stimulation is involved in activation, proliferation, isotype switching, 
germinal center formation and memory cell generation (120). It has been demonstrated 
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that, in B cells, α7 and α9(α10) nAChRs are coupled to CD40, and stimulating α7 
nAChR had an inhibitory effect on CD40-induced proliferation (24). Thus, the reduced 
induction in the CD40 expression on B cells could be related to the fact that ACh is 
activating nicotinic receptors on B cells and resulting in less activation of these cells 
mediated by a reduction in the percentage of CD40
+
 B cells. Like the spleen, PECs of 
paraoxon pre-treated mice showed a moderate increase in the production of IL-12 after 
LPS stimulation but not in un-stimulated cells.  
It is well known that ACh, the main parasympathetic neurotransmitter, stimulates gut 
functions as acid production and intestine motility (121). Thus in our study, an increase 
in the intestine motility could be a mechanism by which bacteria is eliminated from the 
intestinal lumen, not allowing the bacteria to attach to the epithelium  and, consequently 
resulting in the improved survival. Our results showed that after the three weeks of 
treatment with the AChE inhibitor paraoxon, there was no enhancement of the intestinal 
motility and, therefore, ruled out the possibility of decreased contact time between 
bacteria and intestinal epithelium and increased bacterial elimination from the lumen. 
Several studies showed that AChE inhibitors causes and increase in the gastrointestinal 
motility. This effect was proven in an in-vitro study on rat forestomach (122) and others 
in-vivo in conscious dogs (123)  and anesthetized rabbits (124). The difference between 
our study and those studies is that the measurements were taken within minutes or few 
hours of the administration of the AChE inhibitor, while in our study we measured the 
motility after 48 hours of the last injection of paraoxon. This could indicate that 
paraoxon if it has any effect on the intestinal motility, by 48 hours post injection that 
influence can’t be detected. 
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Next, we wanted to evaluate the effect of AChE inhibition pre-treatment on the immune 
response induced by a systemic infection. First, we assessed the immune response to a 
systemic infection with virulent bacteria SL1344. SL1344 is a very virulent bacterium 
that will kill the host within few days, so in these experiments we checked for early 
immune responses along with the bacterial burden in the host body.  Our data showed 
that AChE inhibition did not have a significant impact on the host survival which was 
correlated with the fact that bacterial burden in peritoneal cavity, spleen and liver at 2 
and 20 hours post-infection were similar in pre-treated and non-treated groups. These 
observations were accompanied by no influence of paraoxon on the cell viability in 
PECs and spleen and IL-12 production in serum and spleen cells. So, we thought that 
this systemic infection with virulent SL1344 was masking any influence of paraoxon 
pre-treatment on the host immunity and decided to pursuit a systemic infection using an 




 mutant Salmonella BRD509E.  
BRD509E Salmonella strain lacks the ability to biosynthesize aromatic compound that 
are necessary for the bacterium ability to multiply and, therefore, has a slower 
multiplication rate (115). This is a well stablished model, where bacteria load in the host 
increases and reach its peak by 7-10 days after infection and then the host is able to 
contain the infection and clear the bacteria within 20-30 days after infection (115). Our 
results showed that paraoxon pre-treatment had a mild influence over the host bacterial 
burden at early time point (day 2) only, as paraoxon pre-treated group had a lower 
bacterial burden, in general, and more significantly in the spleen which was correlated 
with lower spleen weights in comparison to control group. This difference was not 
observed in the later time point (day 7) when both groups had comparable bacterial 
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burden and experimented an increase with respect to early time point (day 2). Despite 
the lower bacterial burden at day 2, our treatment did not seem to have any effect on the 
PECs and spleen cells: cell viability, cytokine production, cell phenotype or activation 
markers expression. However, we could explain the lower bacterial burden in the spleen 
at early time point, by the enhanced phagocytic activity of splenic macrophages and the 
moderate increase in IL-12 and IFN-γ production induced by the AChE inhibition.  This 
way, bacteria entering the peritoneal cavity of paraoxon-treated mice could encounter 
stronger macrophages that would limit, initially, their systemic dissemination. 
Additionally, bacteria arriving to the spleen would also find a more hostile environment 
that would limit their growth. This early modest control can’t influence the immunity 
through the whole course of infection, thus lose its effect at later time point (day 7).    
We can speculate that this initial control of the bacterial infection is, probably, lost due 
to the lack of ACh stimulation during the infection.   
Few studies had demonstrated that stimulation of the inflammatory reflex had protective 
effects in sterile sepsis model and different inflammatory diseases models by inhibiting 
the production of pro-inflammatory cytokines thus reducing inflammation 
(28,35,39,40,125). However,  the effect of this pathway in live bacterial infection is 
controversial as in some cases appears to fail to protect the host and to clear the bacteria 
(36). Pro-inflammatory cytokines and neutrophils recruitment are of importance to 
protect the host and clear the bacterium in an infection model; therefore, inhibition of 
the inflammatory response would cause a retarded immune response and result in 
increased bacterial load in the organs, failure to clear the bacteria and subsequently 
worsen the survival of mice. In a mouse model where peritonitis was induced by the 
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injection of E. coli, nicotine administration induced the stimulation of the inflammatory 
reflex that caused a reduction in the production of inflammatory cytokines such as IL-6, 
TNF-α and IL-1β but, these animals had increased their bacterial load in the organs and 
consequently worse host survival in comparison to control (36). However, when α7 
nAChRs knock out mice were used in this model, nicotine effect was reversed and 
bacterial load in these mice was reduced (41). These results are in agreement with our 
own data where we had shown that cholinergic stimulation did not improved the 
immune response to a systemic infection. However, we have to point out the fact that 
paraoxon is an AChE inhibitor and, therefore, increases the Ach levels that, in turn, will 
stimulate both, nicotinic and muscarinic ACh receptors. A recent study had shown that 
the stimulation of  the M3 muscarinic AChR (mAChR) can enhance Th1 responses by 
increasing the production of IFN-γ from CD4 T cells and improve mice survival in a 
systemic attenuated Salmonella infection (44). 
Moreover, it has been shown that ACh and norepinephrine have a stimulatory effect on 
the secretion of secretory IgA in the colonic mucosa (72) but, we were not able to detect 
any changes in the production of anti-Salmonella fecal IgA or total fecal IgA following  
neither systemic nor oral infection in mice previously treated with paraoxon.  
Our and other, results indicated that AChE inhibition did not have any effect on the 
immune response following a systemic infection. All together the data suggested that the 
effects of our treatment are related to the route of infection as it clearly had shown a 
marvelous impact on oral infection model by reducing the bacterial burden in the organs 
and subsequently improved host survival (43).  
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We decided to investigate more in detail the events that followed the oral inoculation of 
SL1344. Early in the infection our results suggested that paraoxon pre-treatment did not 
have any effect either the bacterial burden or serum Il-12 production. Surprisingly, after 
7 days of infection the bacterial growth in the paraoxon-treated group, compared to the 
saline-treated group, was significantly retarded which was accompanied by lower spleen 
weights, lower cytokine production by spleen cells, and lower expression of activation 
markers in spleen and MLNs cells. In addition, serum IL-12 levels remained constant 
throughout the course of infection from day 2 to 7 in paraoxon group. These data 
suggested that the abridged immune responses in paraoxon pre-treated group is related 
to the lower bacterial burden in the different organs in these mice, thus our treatment 
somehow caused a retardation in the bacterial dissemination or growth. In the same 
contest, bioluminescence in-vivo imaging suggested that bacteria was held in the 
abdominal area, most probably the intestine, and took longer time to disseminate to the 
systemic organs. This delay could be due to a lower number of bacteria able to invade 
the intestinal epithelium or/and to a more effective localized immune response able to 
delay the bacterial growth and dissemination. We had mentioned earlier that AChE 
inhibition induced an increase in the activation markers in MLN T cells which could 
indicate a better immune response to the invading bacteria that gets to the MLN from the 
intestine and consequently their elimination. However, other mechanisms could be 
involved in the retention of bacteria at the mucosal and sub-mucosal levels.   
Consequently, we concentrated on studying the effect of AChE inhibition on the gastro-
intestinal tract, particularly the small intestine as it is considered to be the first line of 
defense against oral pathogens.  
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Gene expression of different anti-microbial peptides in the ileum epithelial cells, 
revealed that paraoxon treatment did not enhance the expression of AMPs except a mild 
up-regulation of RegIII-γ which has been shown to have an important role in the defense 
against Gram positive and Gram negative pathogens and the distribution of mucus in the 
ilium (126). This supports our hypothesis that AChE inhibition has a direct effect on the 
intestine immune defense.  
It has been shown that in Salmonella infection, defensins are involved in the clearance 
of the pathogen from the intestinal lumen. In the intestinal epithelial cells, defensins are 
synthesized as pro-defensins that need to be cleaved by the enzyme MMP-7 to become 
active. In a study using MMP-7 knockout mice infected with Salmonella has been 
reported an impaired clearance of the pathogen, showing the important role of defensins 
in defense against Salmonella (56). Furthermore, Angiogenin 4 (Ang4) was found to 
also have bactericidal ability against Salmonella (104). Our study showed an up-
regulation in Defa 1 and 4, RegIIIγ, Ang-4 and MMP-7 enzyme following oral infection 
with Salmonella in normal mice. Thus this up-regulation is a response to the interaction 
of the Paneth cells with the pathogen in order to avoid the invasion of the pathogen.  
However, this up-regulation was much lower in paraoxon-treated mice. Our data also 
showed that paraoxon treatment induced the degranulation of Paneth cells that release 
anti-microbial peptides in response to bacterial stimuli. It has been shown that atropine, 
a muscarinic receptor antagonist, was able to inhibit the secretion of AMPs (81). 
Moreover, it was also demonstrated that bethanechol, a muscarinic agonist, induced  
Paneth cell secretion in mouse intestine by direct  interaction with the muscarinic 
receptors expressed on Paneth cells, indicating that ACh has a regulatory role on the 
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degranulation of AMPs containing granules (80). In our model the degranulation of 
Paneth cells and the release of their AMPs could kill some of the Salmonella bacteria in 
the intestine, leaving only few that could possible interact directly with the Paneth cells 
and induce a further release of AMPs. This could explain the lower expression of AMPs 
in infected mice pre-treated with paraoxon. Furthermore, some studies had demonstrated 
that degranulation and secretion of the content of Paneth cells induced their death (127) 
which support our observations of disintegrated Paneth cells together with young ones. 
A recent study in primary epithelial organoid cultures have showed that Paneth cells 
degranulation is induced by IFN treatment (127). A question that remains to be answer 
is whether AChE inhibition induces the secretion of IFNby intraepithelial 
lymphocytes.  
Cholinergic stimulation is also known to induce mucus secretion in the intestine (79) 
and it was shown to be blocked by atropine indicating that this effect of ACh on mucus 
secretion is derived by stimulation of muscarinic receptors (128). Mucus is an important 
first line of defense to oral pathogen like Salmonella and the more mucus secreted the 
more difficult for the bacteria to penetrate and invade the intestinal epithelium. 
Therefore, the degranulation of goblet cell and, therefore, the increased mucus release in 
paraoxon pre-treated mice could be part of the mechanism by which paraoxon protects 
mice from lethal oral infection. Degranulation of goblet cells and Paneth cells and, 
therefore, the release of mucins and AMPs could be responsible of killing the majority 
of the pathogenic bacteria in the intestinal lumen before they are able to interact and 
penetrate the intestinal epithelium.  This mechanism could explain the hindered bacteria 
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in the gut, the slower dissemination to the systemic organs and low bacterial burden in 
the organs which lead to improved host survival in mice treated with AChE inhibitor.    
One future approach will be to study the immune cells present in the intestinal 
epithelium and lamina propria as AChE inhibition might have some influence on these 
cells as it showed to have on spleen and MLN cells.  
Lastly, our study could open a new perspective about the relationship between nervous 
and immune system and how cholinergic pathway could influence the immunity 














Chapter 7 : Conclusions  
7.1 Conclusions  
 AChE inhibition enhanced immunity after oral but not systemic infection with 
virulent Salmonella. 
 The observed effect is due to enhanced innate immune mucosal defense 
mechanisms as shown by the increased degranulation of immuno-competent 
cells in the GI tract. 
 This could potentially explain the reduction in systemic spread of oral 
Salmonella leading to enhanced survival. 
In conclusion, our data suggest a possible neuro-immune mechanism that leads to 
enhanced host survival after a lethal oral infection model, by enhancing the 
gastrointestinal barrier defense mechanisms, including the secretion of AMPs and 
mucins, as well as increasing macrophages phagocytic activity and T cells activation in 









7.2 Proposed mechanism 
The proposed mechanism by which AChE inhibition modulates the immune response to 
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